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ABSTRACT OF THE DISSERTATION 
 
Histone demethylase LSD1: Connecting developmental signals, chromatin, and cell response 
 
by 
 
Nicholas Kyle Vinckier 
 
Doctor of Philosophy in Biomedical Sciences 
 
University of California, San Diego, 2017 
 
Professor Maike Sander, Chair 
 
 Over the course of development, regulation of gene transcription is the main mechanism 
by which pluripotent stem cells become restricted to the various distinct cell types found in the 
mature organism. Among the many different processes that regulate gene transcription, is the 
control of physical access to DNA and the genes for which it codes. DNA wound around histone 
proteins forms chromatin and the enzymes that modify the landscape of that chromatin control 
which regulatory elements, like promoters and enhancers, are active. This process confers different 
developmental competencies in cells, enabling them to respond uniquely to similar environmental 
and developmental signals, regulating gene transcription in turn. The study of these processes 
during in vitro differentiation of stem cells has enabled us and others to draw links between 
xvi 
chromatin remodelers, transcription factors and cellular response to inductive cues during human 
development. 
In Chapter 1, I explore the role of the lysine-specific demethylase (LSD1) during human 
pancreatic development using an in vitro system to differentiate human embryonic stem cells 
(hESCs) to the pancreatic endocrine lineage. Removal of LSD1 activity during a specific early time 
window of pancreatic development prevents endocrine formation. Investigation into enhancer 
regions occupied by LSD1 during this critical time window provided results that support a model in 
which LSD1-mediated decommissioning renders these enhancers insensitive to activation by 
external retinoic acid signaling. 
In Chapter 2, I report my previous work dissecting the role of the transcription factor 
neurogenin-3 (NGN3) during human pancreatic development. Using the aforementioned hESC-
based in vitro differentiation system, gain and loss-of-function studies showed that NGN3 is both 
necessary and sufficient to induce endocrine formation in human cells. 
A final supplemental chapter provides an example of a hESC-based pancreatic 
differentiation protocol similar to the one employed for the studies outlined in Chapters 1 and 2 and 
discusses the importance of such model systems in dissecting the myriad mechanisms of human 
disease and development.
xvii 
INTRODUCTION 
The human genome is vast, both in the seemingly infinite versions of various traits for which 
it codes, and its cumulative physical length. Each copy of the human genome contains over three 
billion base pairs coding for over 19,000 genes (Morton 1991, Kent, Sugnet et al. 2002, Annunziato 
2008). The sequences coding for these genes are interspersed throughout the genome, separated 
by non-coding intra- and intergenic regions. Many of the non-coding regions contain regulatory 
sequences that recruit various proteins and function to promote, inhibit, insulate and enhance 
transcription of protein coding genes (Wolffe and Pruss 1996). The highly complex string of DNA 
bases contained within a single cell, if arranged end-to-end, would cover a distance of 2 meters 
(Annunziato 2008). To accommodate this great length within the nucleus of a cell, chromosomal 
DNA is coiled around histone protein complexes forming units called nucleosomes. These 
repeating nucleosome units form a “beads on a string” structure that tightly condenses the DNA 
inside the cell nucleus. Nucleosome complexes of histones and DNA and other associated proteins 
are commonly referred to as chromatin (Wolffe and Pruss 1996, Wolffe 2000, Annunziato 2008). In 
addition to tightly packaging the genome into the cell nucleus, this chromatin plays an important 
role in regulating gene expression by controlling the physical accessibility of genes and their 
regulatory sequences to transcriptional machinery (Lee, Hayes et al. 1993, Garcia-Ramirez, 
Rocchini et al. 1995, Wolffe and Pruss 1996, Koch, Andrews et al. 2007, Rossetto, Avvakumov et 
al. 2012, Thurman, Rynes et al. 2012). Rearrangement of histones along a DNA strand can regulate 
transcription of genes by exposing or sequestering these regulatory regions and actual gene coding 
sequences as well (Rossetto, Avvakumov et al. 2012, Shen, Yue et al. 2012). These 
rearrangements are facilitated by covalent post-translation modifications on the tails of histones 
(Garcia-Ramirez, Rocchini et al. 1995, Wolffe and Pruss 1996, Ernst, Kheradpour et al. 2011, Tan, 
Luo et al. 2011). A classic example of this process is the acetylation of lysine 27 on histone H3 
(H3K27ac). The H3K27ac modification is associated with active regulatory elements such as 
promotors and gene-distal regulatory elements called enhancers (Wolffe and Pruss 1996, 
Creyghton, Cheng et al. 2010, Ernst, Kheradpour et al. 2011). At enhancers, the H3K27ac 
1 
2 
modification aids in driving transcription of target genes by making DNA accessible to TFs and 
other DNA-binding protein complexes involved in gene transcription (Wolffe and Pruss 1996, 
Grunstein 1997, Koch, Andrews et al. 2007, Shlyueva, Stampfel et al. 2014). Increasingly, research 
demonstrates the importance of regulatory regions like enhancers and their chromatin state and 
the vital roles they play in proper cell differentiation and function (Rada-Iglesias, Bajpai et al. 2011, 
Whyte, Bilodeau et al. 2012, Xie, Everett et al. 2013, Wang, Yue et al. 2015). 
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CHAPTER 1 - THE ROLE OF LSD1 IN CONNECTING TRANSIENT 
DEVELOPMENTAL SIGNALS AND CELL RESPONSE VIA CHROMATIN REMODELING 
 
ABSTRACT 
 The question of how pluripotent stem cells with identical genomes can develop into the 
various different cell types within a mature organism remains largely unanswered. Many methods 
of gene regulation exist, which ensure proper differentiation of stem cells to their respective cell 
fates. The role of chromatin and the enzymes that remodel it have been increasingly implicated in 
controlling how cells respond to developmental signals and the downstream effect on gene 
transcription during development. The lysine-specific demethylase (LSD1) is one such chromatin 
remodeling enzyme that has been shown to play a vital role in stem cell maintenance and 
differentiation. Here, we investigate the role of LSD1 during human pancreatic development using 
an in vitro system to differentiate human embryonic stem cells (hESCs) to the pancreatic endocrine 
lineage. We find that removal of LSD1 activity during a specific early time window of pancreatic 
development prevents endocrine formation in both humans and mice. Exploration into the genomic 
regions where LSD1 acts during this time window provided evidence for a mechanism wherein 
LSD1 decommissions retinoic acid (RA)-induced enhancers, rendering them insensitive to further 
activation by RA signals, ensuring proper timing of down-regulation of target genes. Here, we show 
the utility of in vitro differentiation systems in studying human development and provide data 
supporting a model in which the chromatin remodeler LSD1 reshapes the chromatin landscape 
altering the developmental competence of differentiating cells. These results provide an example 
of the crucial link between chromatin state and cellular response to developmental signals. 
 
INTRODUCTION 
For multicellular organisms, such as humans, to develop properly, stem cells must 
differentiate into multiple specialized cells. Stem cells by definition are capable of becoming any 
one of the many cell types of the human body (Jaenisch and Young 2008, Hanna, Saha et al. 2010, 
3 
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Rada-Iglesias and Wysocka 2011). Each of the unique and highly specialized cell types within an 
individual contain identical genomic DNA sequences within their respective nuclei (Ernst, 
Kheradpour et al. 2011). This raises the question of how stem cells, indistinguishable from one 
another, can go down such divergent paths to become distinct cell types with completely different 
functional roles. Lineage-determining transcription factors (TFs) play a major role in controlling the 
fates of these multipotent cells by binding to regulatory elements such as gene promoters and distal 
regulatory elements called enhancers to promote target gene transcription (Jaenisch and Young 
2008, Heinz, Benner et al. 2010, Ernst, Kheradpour et al. 2011, Shen, Yue et al. 2012). However, 
the presence of lineage-specific TFs alone cannot account for the various distinct cell types that 
emerge from a common multipotent progenitor pool. To give rise to the numerous types of 
terminally differentiated cells, stem cells, and the lineage intermediates stemming from them, must 
respond to a range of inductive cues throughout embryonic development (Schuldiner, Yanuka et 
al. 2000, Linker and Stern 2004, Heinz, Benner et al. 2010). The timing, duration and localization 
of TF activity and other inductive signals is crucial to proper differentiation, but is not enough to 
explain how and why cells can respond differently to those signals. Increasingly, research into this 
question implicates the chromatin landscape as a major gatekeeper capable of controlling cellular 
response to inductive cues (Shogren-Knaak, Ishii et al. 2006, Heintzman, Hon et al. 2009, Heinz 
and Glass 2012, Pham, Minderjahn et al. 2013, Xie, Everett et al. 2013, Heinz, Romanoski et al. 
2015, Wang, Yue et al. 2015). 
In addition to the aforementioned H3K27ac modification and its role in aiding transcription, 
another example of a histone modification that can modulate target gene expression is the mono-, 
di- and tri-methylation of lysine 4 on histone H3 (H3K4me1/me2/me3). Along with H3K27ac, the 
H3K4me3 modification is associated with active promoters (Bernstein, Mikkelsen et al. 2006, Kim 
and Shiekhattar 2015) whereas the H3K4me1 and H3K4me2 marks are more frequently associated 
with enhancers (Creyghton, Cheng et al. 2010, Heinz, Benner et al. 2010, Wang, Yue et al. 2015). 
Concurrent H3K27ac and H3K4me1/me2 marks are indicative of active enhancers (Heinz and 
Glass 2012, Whyte, Bilodeau et al. 2012, Wang, Yue et al. 2015), while enhancers presenting the 
5 
H3K4me1/me2 modifications alone, are said to be in a “poised” state, ready to be activated upon 
H3K27ac addition (Heinz, Benner et al. 2010, Whyte, Bilodeau et al. 2012, Wang, Yue et al. 2015). 
Histone modifications such as these are mediated by chromatin modifying enzymes that can add 
or remove acetyl groups, methyl groups, phosphates, and ubiquitin on histones (Ernst, Kheradpour 
et al. 2011, Tan, Luo et al. 2011, Thurman, Rynes et al. 2012). It is likely that these chromatin 
remodelers are critical to the cell’s acquisition of developmental competence, the ability of 
multipotent cells respond appropriately to inductive signals from their environment. One chromatin 
remodeling enzyme that has been shown to play an important role in embryonic development is 
the histone demethylase LSD1 (Wang, Hevi et al. 2009, Foster, Dovey et al. 2010, Nair, Ge et al. 
2012, Whyte, Bilodeau et al. 2012, Wang, Yue et al. 2015). LSD1 is a lysine-specific demethylase 
capable of removing mono- and di-methylation modifications from histone H3 (Shi, Lan et al. 2004, 
Wang, Lu et al. 2011, Laurent, Ruitu et al. 2015). Knockout of Lsd1 in mice results in embryonic 
lethality (Wang, Scully et al. 2007) and its activity has been shown to be vital for proper 
maintenance and differentiation of numerous pluripotent cells types from both mice and humans, 
including embryonic, neural, and hematopoietic stem cells (Forneris, Binda et al. 2006, Su, Ying et 
al. 2009, Sun, Alzayady et al. 2010, Zibetti, Adamo et al. 2010, Adamo, Sese et al. 2011, Nair, Ge 
et al. 2012, Whyte, Bilodeau et al. 2012, Kerenyi, Shao et al. 2013, Laurent, Ruitu et al. 2015). 
Research into possible mechanisms through which LSD1 controls cell differentiation has 
identified several roles, including removal of repressive H3K9 mono- and di-methylation marks 
(Metzger, Wissmann et al. 2005, Sun, Alzayady et al. 2010) as well as removal of H3K4 mono- and 
di-methylation at certain enhancers, a process referred to as “decommissioning” (Whyte, Bilodeau 
et al. 2012, Kerenyi, Shao et al. 2013). Whyte and colleagues posited that LSD1-mediated 
decommissioning of certain enhancers, is required to fully suppress genes associated with those 
enhancers. Indeed, when LSD1 was inhibited in stem cells a retention of H3K4 mono- and di-
methylation at LSD1-bound enhancers was observed, which coincided with a failure to fully 
downregulate expression of genes associated with those enhancers (Whyte, Bilodeau et al. 2012). 
The subsequent disruption of stem cell maintenance and differentiation was attributed to the failure 
6 
to decommission these enhancers as a result of LSD1 inhibition. These studies have demonstrated 
a clear link between LSD1-mediated modifications of the chromatin state within a variety of cell 
types, and the ability of those cells to properly function and differentiate. In addition, because LSD1 
activity has been implicated in the proper differentiation of multiple cell lineages, including neurons, 
muscle, blood and adipocytes (Peng, Yerle et al. 2009, Li, Sun et al. 2012, Nair, Ge et al. 2012, 
Xiong, Wang et al. 2016) it is likely that LSD1 plays critical roles in other developmental contexts, 
such as pancreas development. It has been shown that lineage-specific chromatin states confer 
developmental competence in lineage intermediates during pancreatic endocrine differentiation 
(Wang, Yue et al. 2015). This process is critical for proper differentiation and is precisely controlled 
by myriad chromatin modifying enzymes. Previous research has suggested that, in addition to the 
activation and deactivation (addition and removal of H3K27ac) of enhancers, the poising and 
decommissioning (addition and removal of H3K4me1 and H3K4me2) of enhancers plays a vital 
role in ensuring lineage intermediates acquire the developmental competence to become properly 
differentiated cells (Mercer, Lin et al. 2011, Rada-Iglesias and Wysocka 2011, Kaikkonen, Spann 
et al. 2013, Heinz, Romanoski et al. 2015, Wang, Yue et al. 2015). Because LSD1 is known to 
decommission enhancers (Whyte, Bilodeau et al. 2012), and is important for development of a wide 
variety of cell types and tissues, it seemed likely that LSD1 could be one of the chromatin modifiers 
responsible for proper differentiation to the pancreatic endocrine fate. Here, we investigate the 
chromatin remodeling enzyme LSD1 and its role in reshaping the chromatin landscape during 
human pancreatic endocrine development. 
In order to investigate the complexities of human development and disease, researchers 
have turned to the rapidly advancing field of in vitro differentiation of human pluripotent stem cells 
(hPSCs) (Avior, Sagi et al. 2016). With the ability to generate hPSCs from adult somatic cells, it is 
becoming commonplace to differentiate hPSCs derived from individuals with a particular disease 
and assess how those cells behave differently from hPSCs derived from unaffected individuals 
(Takahashi and Yamanaka 2006, Yamanaka 2007, Yamanaka and Blau 2010, Papp and Plath 
2013). With the use of increasingly sophisticated gene editing technologies, researchers can now 
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correct mutations in diseased hPSCs and observe the reversal of the disease state (Xie, Ye et al. 
2014, Hockemeyer and Jaenisch 2016, Zhang, Schmid et al. 2017). Moreover, mutations relevant 
to a disease can be introduced into healthy hESCs and those modified cells can then be 
differentiated to determine how a specific mutation contributes to a particular disease. Individuals 
afflicted by the disease diabetes mellitus stand to benefit greatly from such hPSC-based 
differentiation protocols. Diabetes is characterized by the inability to regulate blood glucose 
homeostasis and is caused by the loss or dysfunction of the insulin-secreting beta cell within the 
islets of Langerhans in the pancreas. Cadaveric islet transplantations have been shown to reverse 
diabetes (Shapiro, Ricordi et al. 2006), which, together with the fact that diabetes typically results 
from the dysfunction of a single cell type, makes the disease a prime candidate for cell-replacement 
therapies. clinical trials for which are currently ongoing (Motte, Szepessy et al. 2014, Schulz 2015). 
Although animal models of diabetes have proven invaluable resources for increasing our 
understanding of pancreas development and diabetes pathogenesis in vivo, hPSC-based in vitro 
pancreatic differentiation systems provide the unique ability to dissect the earliest stages of 
development and can provide virtually limitless material for analysis (Keller 2005). Moreover, the 
ability to generate functional beta cells from hESCs entirely in vitro (Russ, Sintov et al. 2011, 
Pagliuca, Millman et al. 2014, Rezania, Bruin et al. 2014), provides an ideal model system to study 
the proper differentiation and function of the human beta cell. In order to reap the many benefits 
promised by in vitro modeling of diseases like diabetes, it is necessary to first understand how 
healthy cells differentiate and function under normal conditions. The advent of robust hPSC-based 
in vitro differentiation systems has provided researchers with the tools necessary to study any 
number of human diseases and developmental processes entirely in vitro. These systems allow for 
extremely high-resolution spatiotemporal assays of the cell state, enabling the study of complex 
and intricate mechanisms of cellular differentiation on a scale not possible in any other model 
system. By employing one such system, capable of efficiently generating pancreatic endocrine cells 
from human embryonic stem cells (hESCs) (Schulz, Young et al. 2012, Xie, Everett et al. 2013, 
Wang, Yue et al. 2015), we investigated the role of LSD1 in the context of human pancreatic 
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endocrine development, and have begun to dissect the mechanisms by which LSD1 modulates 
developmental competence of cells through remodeling of the chromatin landscape. 
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RESULTS 
Human Endocrine Cell Development Requires LSD1 Activity during a Narrow Time Window early 
in Pancreas Development 
To investigate if LSD1 plays a role during human pancreatic endocrine development, we 
first determined whether LSD1 is expressed during normal human pancreas development. We 
observed high levels of LSD1 expression in human fetal donor (55 days post-conception; dpc) 
pancreatic progenitor cells identified by co-expression of SOX9 and PDX1 (Figure 1A). Additionally, 
co-expression of LSD1 and the endocrine cell marker chromogranin A (CHGA) was observed in 
both human fetal donor (94 dpc) endocrine progenitors and human adult donor (22 years old) islets 
of Langerhans (Figure 1A). LSD1 expression was also observed in multiple endocrine subtypes 
within human adult donor islets, including insulin (INS) expressing beta cells, glucagon (GCG) 
expressing alpha cells, and somatostatin (SST) expressing delta cells (Figure S1A). Using an in 
vitro system to differentiate human embryonic stem cells (hESCs) in a stepwise manner toward the 
pancreatic endocrine cell fate (Schulz, Young et al. 2012, Xie, Everett et al. 2013, Wang, Yue et al. 
2015), we also observed robust LSD1 expression throughout all stages of pancreatic differentiation 
(Figure S1B-S1C). 
Given our observation of LSD1 expression during pancreas development both in vivo and 
in vitro, and the known requirement for LSD1 in proper stem cell differentiation in other contexts 
(Sun, Alzayady et al. 2010, Zibetti, Adamo et al. 2010, Adamo, Sese et al. 2011, Wang, Lu et al. 
2011, Li, Sun et al. 2012, Nair, Ge et al. 2012, Whyte, Bilodeau et al. 2012, Laurent, Ruitu et al. 
2015, Duteil, Tosic et al. 2016), we hypothesized that LSD1 could play a critical role in human 
pancreatic endocrine formation. To assess this, we used the irreversible LSD1 inhibitor 
tranylcypromine (TCP) to block LSD1 activity during directed differentiation of hESCs to pancreatic 
endocrine cells (Figure 1B). Initial attempts to knockdown LSD1 at the ES stage prevented 
progression to the later stages and often resulted in cell death, precluding any study of the role(s) 
of LSD1 at later stages of endocrine differentiation (data not shown). Previous reports have similarly 
shown that LSD1 inhibition in stem cells prevents proper exit from the stem cell state (Sun, 
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Alzayady et al. 2010, Adamo, Sese et al. 2011, Nair, Ge et al. 2012, Whyte, Bilodeau et al. 2012). 
We were therefore prompted to disrupt LSD1 activity during the later stages of differentiation, 
particularly during the formation of pancreatic progenitor and endocrine cells. We first inhibited 
LSD1 during the transition from early (PP1) to late (PP2) pancreatic progenitor stages (LSD1iearly; 
Figure 1B) to determine whether LSD1 is required for proper formation of PP2. Expression of key 
progenitor marker proteins NKX6.1 and PDX1 were largely unaffected in LSD1iearly PP2 cells 
(Figure S1D-S1E). When LSD1iearly cells were further differentiated to the endocrine (EN) stage, 
NKX6.1 and PDX1 expression were again largely unaffected, however no hormone expression was 
observed (Figure 1C-1E), indicating that LSD1 inhibition at this early stage blocked formation of 
endocrine cells. Interestingly, later inhibition of LSD1 during the transition from PP2 to EN cells 
(LSD1ilate; Figure 1B) had no effect on EN cell formation, evidenced by the expression of the 
pancreatic hormones INS, GCG, and SST (Figure 1C-1E). The proteins NKX6.1 and PDX1, which 
continue to be expressed in cells past the progenitor stage and in mature beta cells, were also 
unaffected by the later LSD1 inhibition (LSD1ilate) (Figure 1C-1E). These data indicate that inhibition 
of LSD1 activity is required during the PP1 to PP2 transition to properly form endocrine cells, but 
its activity during the PP2 to EN transition is dispensable for endocrine formation. This suggests 
there is a critical time window in which LSD1 activity is required for generation of endocrine cells 
from hESCs.  
 
LSD1 Inhibition Prevents Enhancer Decommissioning 
To understand why endocrine cell formation requires LSD1 activity during the earlier PP1 
to PP2 transition, but not the later PP2 to EN transition, we performed chromatin 
immunoprecipitation sequencing (ChIP-seq) for LSD1 at the PP1 stage to identify regions in the 
genome where LSD1 could be acting during this stage of differentiation. We identified 15,084 
LSD1-bound peaks (Table S1) throughout the genome (Figure S2A). Of these, 3,285 were proximal 
(< 3 kb) to a transcription start site (TSS) and 11,799 were distal (> 3kb) to any TSS (Tables S2 
and S3, respectively). Because LSD1 is known to associate with and modify enhancers (Whyte, 
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Bilodeau et al. 2012, Kerenyi, Shao et al. 2013) and cell type-specific enhancers are known to 
determine cell lineages (Heintzman, Hon et al. 2009, Heinz and Glass 2012, Heinz, Romanoski et 
al. 2015, Romanoski, Link et al. 2015, Wang, Yue et al. 2015), we investigated the distal regions 
bound by LSD1, which comprise the majority (~78%) of LSD1 peaks at the PP1 stage.  
To begin to characterize the chromatin states during the PP1 to PP2 transition, we 
performed ChIP-seq for H3K27ac at the PP1 and PP2 stages. Because the H3K27ac modification 
has been widely shown to be a faithful indicator of active enhancers (Heintzman, Hon et al. 2009, 
Creyghton, Cheng et al. 2010, Zentner, Tesar et al. 2011, Zentner and Scacheri 2012), we used it 
here to categorize distal LSD1 peaks at PP1 into one of three enhancer groups (Figure 2A). The 
enhancer groups were defined as follows: Group 1 (G1) consists of LSD1-bound regions where 
H3K27ac decreases ≥ 2-fold from PP1 to PP2; Group 2 (G2) consists of LSD1-bound regions where 
H3K27ac does not change more than 2-fold (either increase or decrease) from PP1 to PP2; Group 
3 (G3) consists of LSD1-bound regions where H3K27ac increases ≥ 2-fold from PP1 to PP2 (Figure 
2A and Tables S4-S6). In essence, G1 enhancers deactivate from PP1 to PP2, G2 enhancers 
remain active from PP1 to PP2, and G3 enhancers become active from PP1 to PP2. LSD1 ChIP-
seq revealed that LSD1 binding remains unchanged from PP1 to PP2 at G2 and G3 enhancer 
regions, but is largely decreased at G1 enhancers during this transition (Figure 2B). To further 
characterize the groups of LSD1-bound enhancers we next performed ChIP-seq for H3K4me1 and 
H3K4me2 at the PP1 and PP2 stages. Along with the H3K27ac mark, H3K4me1 and H3K4me2 
are very often observed at active enhancers (Heinz and Glass 2012, Whyte, Bilodeau et al. 2012, 
Heinz, Romanoski et al. 2015, Wang, Yue et al. 2015). Enhancers that possess these marks, but 
lack H3K27ac are said to be in a “poised” state; ready to be activated following H3K27ac addition, 
or decommissioned through removal of methylation from H3K4 (Creyghton, Cheng et al. 2010, 
Rada-Iglesias, Bajpai et al. 2011, Whyte, Bilodeau et al. 2012, Wang, Yue et al. 2015). 
Furthermore, LSD1 is known to demethylate both H3K4me1 and H3K4me2, and although H3K9 
mono- and di-methylation are substrates of LSD1 (Metzger, Wissmann et al. 2005, Wissmann, Yin 
et al. 2007, Zibetti, Adamo et al. 2010, Laurent, Ruitu et al. 2015), we observed no expression of 
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the transcript encoding the H3K9 demethylating isoform of LSD1 (LSD1+8a) (data not shown). We 
therefore specifically assayed for mono- and di-methylation of H3K4 and not H3K9. Both H3K4me1 
and H3K4me2 levels are significantly decreased from PP1 to PP2 at G1 enhancers (Figure 2C), 
further evidence this group can be classified as “deactivating” during this transition. Similarly, 
changes in H3K4me1 and H3K4me2 from PP1 to PP2 at G2 and G3 enhancers support their 
classifications of “remaining active” and “activating”, respectively. To determine if the normal 
demethylation of H3K4 seen in G1 enhancers was dependent upon LSD1 activity, we next 
performed ChIP-seq for H3K4me1 and H3K4me2 in LSD1iearly PP2 cells. Indeed, when LSD1 was 
inhibited at PP1 there was a failure to remove both H3K4me1 and H3K4me2 marks in G1 (Figure 
2D; compare blue and red plot lines). These data suggest that, during the PP1 to PP2 transition, 
LSD1 acts to decommission G1 enhancers, but not G2 and G3 enhancers, through removal of 
H3K4 mono- and di-methylation before vacating those regions. Interestingly, H3K27ac ChIP-seq 
in LSD1iearly PP2 cells revealed that the deactivation of G1 enhancers (H3K27ac removal) was not 
disrupted by LSD1 inhibition (Figure 2D), suggesting that the deactivation of these enhancers can 
be decoupled from their decommissioning. This evidence supports models from previous reports 
that proposed enhancer deactivation and decommissioning as two separate events, each with an 
important role in enhancer regulation (Koch, Andrews et al. 2007, Whyte, Bilodeau et al. 2012). A 
similar decoupling of H3K27ac and H3K4 methylation states was also seen in G2 and G3 
enhancers (Figure S2B). All together these results suggest the existence of a set of LSD1-bound 
enhancers that are typically deactivated and decommissioned during the PP1 to PP2 transition 
under normal differentiation conditions (G1 enhancers). When LSD1 is inhibited during this 
transition the deactivation events still occur at G1 enhancers, but the subsequent decommissioning 
is blocked, leaving the enhancers in a poised state (Figure 2E). We therefore hypothesized that 
maintenance of G1 enhancers in a poised state at PP2 as a result of LSD1 inhibition at PP1 could 
affect the expression of genes associated with these enhancers. 
 
LSD1 Represses Transiently Expressed, Retinoic Acid-Dependent Genes 
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To better comprehend the nature of G1 enhancers and their role in controlling target gene 
expression, we first annotated transcription factor (TF) binding motifs at LSD1 bound enhancers. 
Motif enrichment analysis was performed with HOMER (Heinz, Benner et al. 2010) using the 
combined set of G2 and G3 enhancers as the background over which enrichment was calculated. 
We found that the motif for retinoic acid receptor (RAR) and retinoid X receptor (RXR) heterodimer 
(RAR/RXR) was highly enriched in G1 enhancers (Figure 3A). When retinoic acid binds to RAR, 
the RAR/RXR heterodimer associates with coactivating proteins, which, in turn, effect RA-induced 
events within the nucleus, including transcription of target genes and enhancer activation (Mahony, 
Mazzoni et al. 2011, Rhinn and Dolle 2012, Cunningham and Duester 2015). Because there are 
multiple isoforms of RAR that can heterodimerize with multiple isoforms of RXR, we used a pan-
RXR binding antibody to perform ChIP-seq for RXR in PP1 cells to identify all regions where RA 
might be able to elicit a response by binding to one of the various isoforms of RAR within a 
RAR/RXR heterodimer. We found that 45.5% of G1 enhancers were co-occupied by RXR 
(612/1345; compared to an expected 5.6% by random chance), within ± 10kb of the center of the 
corresponding LSD1 peak, at the PP1 stage (Figure 3B and Table 1). We also found overlapping 
RXR binding with G2 and G3 enhancers to be higher than expected by random chance; however, 
the amount of overlap with G1 enhancers was significantly higher than that observed in G2 and G3 
enhancers (Figure S3A). We further analyzed the RXR-bound G1 enhancers and found that this 
subset of enhancers normally undergoes a sharp increase in H3K27ac during the gut tube (GT) to 
PP1 transition, followed by an equally abrupt decrease in H3K27ac from PP1 to PP2 (Figure 3C). 
This acute acetylation and deacetylation of RXR-bound G1 enhancers coincides precisely with the 
addition and removal of exogenous RA in the cell culture media, as part of the normal differentiation 
protocol (Figure 3C) (D'Amour, Bang et al. 2006, Kroon, Martinson et al. 2008, Schulz, Young et 
al. 2012). This suggests that these enhancers follow an RA-dependent activation pattern. Notably, 
the large decrease in H3K27ac from PP1 to PP2 also occurs when LSD1 is inhibited at PP1 
(LSD1iearly) (Figure 3C) indicating this specific subset of G1 enhancers is still being deactivated 
during this transition, as was seen for G1 as a whole (Figure 2D). Additionally, as occurred at all 
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G1 enhancers, LSD1 inhibition likewise prevented removal of H3K4me1 and H3K4me2 at RXR-
bound G1 enhancers (Figure S3B). 
Our analysis identified 612 RXR-bound G1 enhancers, which we used with the Genomic 
Regions Enrichment of Annotations Tool (GREAT) (McLean, Bristor et al. 2010) to identify 634 
potential target genes (Table 2). To better understand how these RXR-bound G1 enhancers might 
affect target gene expression we performed RNA-seq on GT, PP1, and PP2 control and LSD1iearly 
cells. The RNA-seq data was then analyzed to obtain normalized gene expression levels 
(fragments per kilobase per million mapped reads; FPKM) for each of the genes across the time 
course, from GT to PP1 to PP2 ± LSD1iearly. We next performed k-means cluster analysis on all 
634 genes, based on their expression changes across the GT, PP1, and PP2 differentiation stages, 
to isolate groups of genes that share common expression patterns over this time course. This 
revealed several categories of genes including one group consisting of 95 genes with increased 
expression from GT to PP1 followed by a sharp decrease in expression from PP1 to PP2 (Figure 
3D; yellow bounding box). This expression pattern showed a striking resemblance to the H3K27ac 
pattern observed for the 612 RXR-bound G1 enhancers, and included within it enhancers of several 
genes well-known to be induced by RA, such as HOXA1, HOXB1, RARB, and DHRS3 (Balmer and 
Blomhoff 2002, Balmer and Blomhoff 2005, Kam, Shi et al. 2013). We then queried the entire set 
of 634 genes to identify all genes that exhibited this same RA-dependent expression pattern. 
Specifically, we selected genes with FPKM ≥ 1 at PP1, ≥ 2-fold increase from GT to PP1, and ≥ 2-
fold decrease from PP1 to PP2. Of the 634 genes, 74 met all three criteria (Table 3) of which 74.3% 
(55 of 74) were also included in the group of 95 genes identified through cluster analysis. 
Interestingly, when LSD1 is inhibited at PP1 (LSD1iearly) there is a significant failure to down-
regulate many of the 74 genes (Figure 3F), including several known to be induced by RA (Figure 
S3C). During the PP1 to PP2 transition, LSD1 inhibition does not disrupt the removal of H3K27ac 
from the RXR-bound G1 enhancers associated with these genes, including known RA-induced 
genes like HOXA1, HOXC4, GATA4, and DHRS3 (Figures 3G and S3D), thus allowing deactivation 
of the enhancers. However, when LSD1 is inhibited removal of H3K4me2 is blocked, preventing 
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the decommissioning of these enhancers and leaving them in a poised state (Figures 3G and S3D). 
Taken together, these results suggest that LSD1-mediated decommissioning of RXR-bound G1 
enhancers is required to fully repress expression of their target genes. 
 
Prolonged Exposure of early Pancreatic Progenitors to Retinoic Acid Phenocopies LSD1 Inhibition 
Our data indicate that LSD1 is required to convert RXR-bound G1 enhancers from a poised 
to a decommissioned state and that LSD1 inhibition during this transition (LSD1iearly) disrupts that 
process, allowing for continued expression of target genes. Because LSD1 inhibition locks these 
enhancers in a poised state, it is possible they remain receptive activating RA signals, which, in 
turn, could prevent repression of genes that must be silenced after PP1 for proper endocrine 
formation to occur. With this in mind, we hypothesized that prolonged exposure of differentiating 
cells to RA signaling through the PP1 stage (Figure 4A) would be sufficient to prevent repression 
of these same genes and ultimately prevent downstream endocrine formation, mimicking the 
LSD1iearly phenotype. The extended treatment of PP1 cells with RA (RAextended) resulted in an overall 
failure to downregulate the 74 genes within the previously identified group associated with RXR-
bound G1 enhancers. The significantly higher expression of these genes as a whole in RAextended 
PP2 cells mimics the gene dysregulation observed in LSD1iearly PP2 cells. Of the 74 PP1-specific 
genes associated with RXR-bound G1 enhancers, 48 (~65%) failed to be repressed in PP2 cells 
when RA exposure was extended through the PP1 to PP2 transition (RAextended), including several 
of the previously identified genes known to be induced by RA (Figure 4B, 4C and 4SA). 
Remarkably, when RAextended cells were differentiated to the EN stage, almost no expression of 
pancreatic hormone proteins or mRNA was observed (Figures 4D, 4E and S4B). Protein expression 
of NKX6.1 and PDX1 at the EN stage were unaffected by extended RA treatment (Figure 4E and 
S4C). This phenotype was nearly identical to that observed when LSD1 was inhibited in early (PP1) 
pancreatic progenitors (LSD1iearly). The observed phenocopy of LSD1iearly as a result of extended 
RA treatment (RAextended) and the identification of RXR-bound enhancers that are remodeled by 
LSD1, provide evidence in support of the existence of a link between LSD1-mediated 
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decommissioning of RXR-bound G1 enhancers and the cells ability to respond to external RA 
signals. Together, these results suggest the possibility that the mechanism by which LSD1iearly 
prevents the formation of endocrine cells could be mediated by the failure to decommission RXR-
bound G1 enhancers, thus leaving them in a poised state in which they remain susceptible to RA 
signals. This, in turn, prevents the repression of target genes necessary for proper endocrine 
formation. However, there remains the possibility that aberrant RA signaling alone could disrupt 
endocrine formation, in a manner independent of the chromatin state at RXR-bound G1 enhancers. 
 
LSD1 Prevents Aberrant Reactivation of Transient early Retinoic Acid-dependent Genes 
To determine if cells in which G1 enhancers have already been decommissioned are still 
susceptible to RA-induced blockage of endocrine formation, we reintroduced RA into the 
differentiation media during the PP2 to EN transition (RAlate; Figure 5A). Unlike the phenotype 
observed in RAextended EN cells, formation of pancreatic endocrine cells was unperturbed in RAlate 
EN cells (Figure 5B). Expression of NKX6.1 and PDX1 was also unaffected (Figures 5C and S5A), 
and although mRNA levels for the pancreatic hormones INS, GCG and SST decreased as a result 
of RAlate (Figure S5B), respective protein expression appeared similar to controls (Figures 5B and 
5C). In contrast to the up-regulation of PP1-specific genes associated with RXR-bound G1 
enhancers observed in LSD1iearly and RAextended PP2 cells, no significant change was seen for these 
74 genes in RAlate EN cells (Figures 5D and S5C). Surprisingly, several of the previously identified 
genes shown to be induced by RA remained unchanged in RAlate EN cells (Figure 5E). Moreover, 
some of the genes that were increased in RAextended PP2 cells, including DHRS3 and SHH were 
actually decreased in RAlate EN cells (Figure 5E). This indicates that whereas extended RA 
treatment through the PP1 to PP2 transition, the late addition of RA (RAlate) was not sufficient to 
induce the same upregulation of these genes. These data suggest that at different stages of 
differentiation cells respond differently to the same RA signaling molecule, signifying shifts in the 
cellular contexts as cells transition from one lineage intermediate to the next. 
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This change in developmental competence was further demonstrated when RA was 
reintroduced to LSD1iearly cells during the PP2 to EN transition (LSD1iearly + RAlate). In this case, 
many of the PP1-specific genes associated with RXR-bound G1 enhancers were up-regulated 
compared to LSD1iearly EN cells (Figure 5H and S5E/I). Perhaps unsurprisingly, late addition of RA 
to LSD1iearly PP2 cells (LSD1iearly + RAlate) resulted in a lack of endocrine cells at the EN stage, 
similar to LSD1iearly alone (Figure 5G). Interestingly, however, while LSD1iearly alone tended to result 
in upregulation of many of 74 PP1-specific genes associated with RXR-bound G1 enhancers, the 
late addition of RA in LSD1iearly PP2 cells (LSD1iearly + RAlate) caused even further upregulation of 
several of these genes (Figure 5E). These results indicate that late addition of RA to PP2 cells 
(RAlate) causes increased expression of many of the PP1-specific genes associated with RXR-
bound G1 enhancers, if LSD1 has been previously inhibited during the transition from PP1 to PP2 
(LSD1iearly). Without prior LSD1 inhibition, this same up-regulation of genes was not observed in 
RAlate EN cells. Together, these data suggest that LSD1 activity during the PP1 to PP2 transition is 
required to prevent reactivation of RA-dependent genes at later stages of differentiation. 
 
Requirement for Lsd1 in Endocrine Cell Formation during a Short Window in early Pancreatic 
Development in mice 
To confirm the phenotype observed during pancreatic differentiation of hESCs in an in vivo 
setting, we mimicked the removal of LSD1 activity using a genetic knockout approach in mice. To 
determine if Lsd1 plays a role in mouse pancreas development, similar to that observed in human 
differentiation, we first analyzed its expression pattern in the developing and adult mouse pancreas. 
We found that, as in humans, Lsd1 is expressed in the early multipotent pancreatic progenitors 
(marked by Pdx1/Sox9 co-expression) in the developing mouse embryo, as well as in embryonic 
and adult endocrine cells. (Figure S6A). Robust Lsd1 expression was also observed in multiple 
endocrine subtypes in adult mouse islets (Figure S6B). To explore the function of Lsd1 during 
mouse pancreas development, we selectively inactivated Lsd1 in early pancreatic progenitor cells 
by generating Pdx1Cre;Lsd1flox/flox (Lsd1Δpan) mice (Figure 6A). In Lsd1Δpan embryos, key aspects of 
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early pancreatic development, such as the induction of early pancreatic markers and outgrowth of 
the tissue buds, were unperturbed (Figure 6B, 6C and S6C). Furthermore, expression of acinar 
and ductal markers, and cell survival were unaffected by Lsd1 deletion (Figure S6C and S6D). 
However, by embryonic day (e) 15.5, when widespread endocrine cell differentiation is evident in 
control mice, Lsd1Δpan embryos exhibited a complete lack of endocrine cells (Figure 6B), which 
remained apparent at birth (Figure 6D). These findings revealed that, as in humans, Lsd1 
inactivation during pancreas development in mice prevents endocrine formation. This suggests that 
Lsd1 is required for endocrine lineage specification in mice.  
To determine if a critical time window exists during which Lsd1 expression is critical for 
proper mouse pancreatic endocrine formation, as was observed during differentiation of hESCs, 
we crossed Lsd1flox/flox and Pdx1CreERTM mice, allowing for time-specific inactivation of Lsd1 in 
pancreatic progenitors via tamoxifen administration (Figure 6E). Tamoxifen injection at e12.5 
(Lsd1Δlate) targeted the multipotent pancreatic progenitor domain shortly before endocrine cell 
differentiation (Seymour and Sander 2011) and did not affect endocrine cell formation, as 
evidenced by the presence of LSD1-deficient hormone+ cell clusters in LSD1 (Figure 6F and S6E). 
By contrast, tamoxifen administration at e10.5 (Lsd1Δearly) resulted in almost complete loss of 
endocrine cells, phenocopying Lsd1Δpan mice (Figure 6F and S6E). Given the delay between 
tamoxifen administration and gene deletion (Nakamura, Nguyen et al. 2006), these results indicate 
a time window between e11 and e13 during which Lsd1 deletion prevents endocrine formation. 
This suggests that Lsd1 activity is required during a specific early time window of mouse pancreas 
development, after which it is dispensable, for proper endocrine cell differentiation. These data 
provide in vivo confirmation of the phenotype observed when LSD1 is inhibited during in vitro 
differentiation of hESCs to the pancreatic endocrine lineage.  
Of the 74 PP1-specific genes associated with RXR- bound enhancers identified in hESC-
based LSD1 inhibition studies, 51 were expressed in either control or Lsd1Δpan mutant mice at 
e13.5. Overall, expression of these genes was increased in Lsd1Δpan compared to controls (Figure 
6G and S6F). Among these 51 genes several showed significant up-regulation in Lsd1Δpan 
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compared to control, including Hoxa1 Hoxc4 and Cadm3 (Figure 6H). All of these were similarly 
found to be up-regulated during LSD1 inhibition and induced by RA treatment in pancreatic 
differentiation of hESCs (Figures S3C, 4C and 5E/I). This indicates that, in addition to blocking 
endocrine formation, Lsd1 knockout in early mouse embryos causes up-regulation of several genes 
previously shown to be induced by RA in during pancreatic differentiation of hESCs. This suggests 
that Lsd1 may act in a similar capacity during mouse pancreas development as it does during 
human pancreatic differentiation; wherein, Lsd1 deletion, prevents Lsd1-mediated 
decommissioning of associated RA-responsive enhancers. Without Lsd1 present to decommission 
these enhancers they remain susceptible to activation by circulating RA, which ultimately prevents 
the normal repression of target genes that is required for proper endocrine formation. 
These results not only confirm the phenotype observed in hESCs, but also lend credence 
to the utility of hPSC-based in vitro systems in studying and dissecting processes of human 
development. With an in vitro differentiation system however, signaling factors such as RA can 
simply be withdrawn from the differentiation media at specific times to prevent further influence on 
the differentiating cells. In contrast, during in vivo development, many of these signaling molecules 
persist constitutively and the cellular response to these signals must be altered in precise 
spatiotemporal manner in order for multipotent progenitors to respond appropriately and 
differentiate into the correct cell types, thus ensuring proper development of fully functional organs. 
Altogether, these results support a model wherein LSD1-mediated decommissioning of enhancers 
functions to render cells insensitive to external developmental cues, effectively altering the 
developmental competence of the cells by reshaping the chromatin landscape.  
 
DISCUSSION 
Here, we have identified a specific time window during early pancreatic development in 
both human and mouse, in which LSD1 activity is required for pancreatic endocrine formation. We 
found that during this time window, LSD1 is localized to different classes of enhancers (Figure 2A). 
One of those LSD1-bound enhancers groups (G1) normally undergoes deactivation and 
decommissioning. Upon inhibition of LSD1 those enhancers are still deactivated (H3K27ac 
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removal), but decommissioning (H3K4me1/H3K4me2 removal) is disrupted (Figure 2D). Genomic 
regions within the G1 enhancer group were enriched for RXR binding motif; and indeed, nearly half 
of G1 enhancers were co-bound by RXR during this time window (Figure 3A). The inclusion of RA 
in the differentiation media during the transition prior to this critical time window is coincident with 
the activation of these enhancers (Figure 3D). Together these results indicate these enhancers 
may be responsive to the RA in the differentiation media and suggest they are first activated by 
RA, and later decommissioned by LSD1 when the enhancer needs to be fully repressed and 
prevented from future reactivation. Previous models of LSD1 control of enhancers suggest that 
LSD1-mediated demethylation of H3K4 at enhancers is required to properly decommission the 
enhancers and repress target genes (Whyte, Bilodeau et al. 2012). Consistent with this model, our 
results indicates LSD1 is required to convert these enhancers from a poised to a decommissioned 
state. This, along with the observed concomitant failure to down-regulate many of the genes 
associated with RXR-bound G1 enhancers, suggest that LSD1 inhibition during this transition 
(LSD1iearly) disrupts decommissioning of RA-activated enhancers and allows for continued 
expression of target genes.  
Our findings provide evidence that suggests proper modulation of chromatin landscape is 
vital to ensuring cells respond appropriately to external inductive signals. The results presented 
here provide evidence in support of a model in which LSD1 occupies a group of RA-responsive 
enhancers that become active following exposure to RA during the GT to PP1 transition. During 
the transition to PP2 these enhancers are deactivated and LSD1 decommissions them, rendering 
them insensitive to external RA signals. This, in turn, allows for appropriate repression of target 
genes, even in the event the cells are re-exposed to RA. However, when LSD1-mediated 
decommissioning of these enhancers is blocked during the PP1 to PP2 transition these enhancers 
are left in a poised state. The poised enhancers remain susceptible to reactivation when exposed 
to RA signals, which, in turn, induces aberrant reactivation of target genes. A prime example of this 
was observed in the regulation of the gene DUSP9. During normal differentiation DUSP9 
expression increases from GT to PP1, where it peaks, before being downregulated in PP2. DUSP9 
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is known to be activated by RA (Simandi, Balint et al. 2010), but it was not up regulated in LSD1iearly 
PP2 cells. However, it is up-regulated at the EN stage when RA is added late (RAlate) to PP2 cells, 
but only if LSD1 was previously inhibited at the PP1 stage (LSD1iearly). This finding supports the 
model wherein the failure of LSD1 to decommission enhancers may not cause immediate up-
regulation of potential target genes, but rather leaves the enhancers in a poised state, providing a 
permissive environment for enhancer reactivation. In fact, although LSD1iearly does not cause an 
upregulation of DUSP9 at the PP2 stage, when measured at the later EN stage, DUSP9 expression 
is elevated in LSD1iearly cells compared to EN controls. It is therefore possible that this gene, and 
others like it, are normally down-regulated after LSD1-mediated decommissioning of their 
associated enhancers; and, when those enhancers are not properly decommissioned, as a result 
of removal of LSD1 activity, they remain poised and susceptible to future reactivation, given the 
right inductive cues. The data shown here highlight the role of LSD1 as an important chromatin 
remodeler during development, and suggest that its ability to reshape the chromatin landscape of 
differentiating cells can alter the developmental competence of those cells, influencing their 
responses to developmental signals. 
Developmental signals like RA are extremely important for development of a variety of 
tissues, including neurons, lung and pancreas (Durston, Timmermans et al. 1989, Avantaggiato, 
Acampora et al. 1996, Bibel, Richter et al. 2004, Plachta, Bibel et al. 2004, Mark, Ghyselinck et al. 
2009). The importance of RA in pancreas development has been well established (Chen, Pan et 
al. 2004, Martin, Gallego-Llamas et al. 2005, Molotkov, Molotkova et al. 2005). These and other 
studies have demonstrated that for proper development to occur, different lineage intermediates 
must be exposed to RA at different times and concentrations and for different durations; and that 
each of these aspects are vary between, and are specific to each individual cell type. During in vitro 
differentiation of cells it is trivial to supply signaling factors at specific times and concentrations and 
durations, as needed. This is, in fact, one of the great benefits to these systems that allows for 
precise control of the signaling environment and the generation of highly pure populations 
consisting of a single cell type. However, during in vivo development many cells remain exposed 
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to these signaling factors before and after they must respond to them, raises the question of how 
these cells can modulate their responses to these developmental cues. 
Using our in vitro model system, we gathered evidence that establishes a link between 
modification of the chromatin landscape by LSD1 during differentiation and the resulting changes 
in cellular response to external developmental signals. Here we have presented results that begin 
to explain one possible mechanism of how seemingly identical stem cells, with identical genomes, 
can respond to the same cues in very different ways and give rise to the wide variety of specialized 
cell types observed in the human body 
 
METHODS 
Chromatin immunoprecipitation followed by massively parallel multiplexed sequencing (ChIP-seq) 
ChIP-seq was performed using the ChIP-IT High-Sensitivity kit (Active Motif) according to 
the manufacturer’s instructions. Briefly, for each cell stage and condition analyzed, 5-10 x 106 cells 
were harvested and fixed for 15 min in an 11.1% formaldehyde solution. Cells were lysed and 
homogenized using a Dounce homogenizer and the lysate was sonicated in a Bioruptor® Plus 
(Diagenode), on high for 3 x 5 min (30 sec on, 30 sec off). Between 10 and 30 µg of the resulting 
sheared chromatin was used for each immunoprecipitation. Equal quantities of sheared chromatin 
from each sample were used for immunoprecipitations carried out at the same time. 4 µg of 
antibody against LSD1 (Abcam, ab17721), H3K4me1 (Abcam, ab8895), H3K4me2 (Millipore, 07-
030), H3K27ac (Active Motif, 39133) and RXR (Santa Cruz, sc-831) were used for each respective 
ChIP-seq assay. Chromatin was incubated with primary antibodies overnight at 4 °C on a rotator 
followed by incubation with Protein G agarose beads for 3 hours at 4 °C on a rotator. Reversal of 
crosslinks and DNA purification were performed according to the ChIP-IT High-Sensitivity 
instructions, with the modification of incubation at 65 °C for 2-3 hours, rather than at 80 °C for 2 
hours during crosslink reversal. Sequencing libraries were constructed using KAPA DNA Library 
Preparation Kits for Illumina® (Kapa Biosystems) and library sequencing was performed on a HiSeq 
4000 System (Illumina®). Both library construction and sequencing were performed by the Institute 
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for Genomic Medicine (IGM) core research facility at the University of California at San Diego 
(UCSD). 
 
Chromatin mapping and data quality control 
 Sequencing data was released from the UCSD IGM core facility after passing internal 
quality controls and certain benchmarks set forth by the FastQC analysis software (Andrews 2010), 
including total sequence reads, sequence quality and length distribution scores. Upon receipt of 
raw sequencing data (FASTA format), several downstream analyses were performed to ensure 
quality of sequencing data. First, all ChIP-seq data was mapped to the human genome utilizing the 
most recent consensus build (hg19/GRCh37) of the human genome available at the time of this 
study (Kent, Sugnet et al. 2002). Bowtie 2, v2.2.7 (Langmead and Salzberg 2012) was used to map 
data to the genome using the parameters defined in Table 4. Next, further quality control steps to 
confirm the sequence data was of acceptable quality were performed post-mapping using the 
Samtools v1.3.1 (Li, Handsaker et al. 2009) and HOMER v4.9 (Heinz, Benner et al. 2010) software 
suites (see Table 4). Various attributes of each sequence file were assessed to ensure the 
sequence reads met certain criteria. The number of reads not mapped to the genome build had to 
be within a reasonable range (1 - 2%) of the total mapped reads. Note: Because we mapped to a 
consensus reference genome, it is possible that unmapped reads represent real portions of the 
genome from the cells being analyzed, but that these sequences are for one reason or another not 
contained within the reference genome. However, for the purposes of this study, unmapped reads 
were discarded. A high percentage of unmapped reads could indicate an experimental problem 
with the immunoprecipitation itself, contaminating DNA from non-human sources or an issue with 
library preparation, such as the amplification of indexing primer dimers (O'Geen, Echipare et al. 
2011, Head, Komori et al. 2014). 
 Another important quality control metric is the number of exact duplicate reads within a 
sequence file. Due to the nature of ChIP-seq, it is somewhat unlikely that two reads will have exactly 
the same sequence and length (Storvall, Ramskold et al. 2013). A high number of exact duplicates 
24 
could indicate a problem arising from the library preparation and sequencing. However, it is not 
always the case that a duplicate is an artifact and visualization of the data on a genome browser 
might help to distinguish between artifacts and true data. One last key metric is that of the 
multimapping read. Those reads that map to > 1 genomic region cannot effectively be used as their 
true position cannot be determined via the ChIP-seq method. The methods used here to align 
sequence reads to the genome were not based on perfect 1:1 matches, but rather allowed for 
certain degrees of freedom each time a read was mapped to account for potential sequencing 
errors and/or DNA bases that are reported as low confidence by the sequencing platform. With this 
in mind, we relied on the mapping quotient (MAPQ) scores assigned to each read during alignment 
to the genome. A certain level of confidence that a read is correctly mapped and only maps to one 
location is provided by the MAPQ score. If the probability that a read is incorrectly matched is equal 
to P and P is a value between 0 and 1 (0 to 100% probability), then the MAPQ score is generated 
by -10 x log10(P). A MAPQ score of 0 means the fragment definitely maps to > 1 place. If the 
estimate that a read maps to > 1 region is 100% then P = 1 and MAPQ = -10 x log10(1) = 0. 
Conversely, if the probability that a fragment matches exactly one genomic region is 99.9% or 
0.999, then the probability of a mismatch is P = 1 - 0.999 = 0.001 and the MAPQ = -10 x log10(0.001) 
= 30. So, anything with a MAPQ score > 30 has an estimated chance of improper matching of less 
than 0.1%. For the purposes of this study, all reads with MAPQ > 0 were used. Ultimately, a 
sufficient amount of uniquely mapped reads from each ChIP-seq experiment are required and 
previous standards have been set by consortia like ENCODE (Encode Project Consortium 2012), 
which required >= 10 and 20 million uniquely mapped reads for TF and histone modification ChIP-
seq experiments, respectively. All ChIP-seq experiments in this study meet or exceed these 
requirements. 
 After confirming sufficient reads of acceptable quality were mapped to the genome, we 
next measured the overall GC content of the uniquely mapped sequences to ensure it fell within 
expected ranges. This value can vary widely across all samples, but should be closely reproduced 
in biological replicates of the same cell, condition and protein immunoprecipitated. Our major 
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concern was to ensure that, within a single ChIP-seq experiment, the distribution of GC content 
was somewhat normal (Gaussian), or skewed high or low. If the experiment exhibits a bimodal 
distribution of GC content, with high percentages of both high and low GC content sequences, this 
could indicate a problem with the experiment, such as contamination of the immunoprecipitated 
DNA or library preparation (Head, Komori et al. 2014). 
 
Peak calling and visualization of ChIP-seq data 
 Mapped ChIP-seq data served as inputs to generate tag directories using HOMER (Heinz, 
Benner et al. 2010). Tag directories take all mapped reads from the input and generates a "tag" 
spanning the appropriate chromosomal coordinates. The tags "stack" on one another to eventually 
generate piles of reads over certain locations which can then be called as peaks, as was done here 
using the findPeaks program within the HOMER software suite. Stage- and condition-matched input 
DNA controls were used as background when calling peaks. The Bedtools v2.17.0 (Quinlan and 
Hall 2010) suite of programs was used to quickly analyze whether certain peaks overlapped with 
other peaks or modified histone regions. For example, windowBed was used for initial in silico pilot 
experiments to classify enhancers based on H3K27ac states from PP1 to PP2. This was a simple 
binary call using the peak files generated in HOMER to determine whether a peak in PP1 was 
within ± 1000 bp of a peak in PP2. This was the initial method used to generate the different 
classifications of enhancers (i.e. active in PP1 and inactive in PP2). This served as a fast initial 
screen to identify interesting patterns in the ChIP-seq data. However, the binary nature of these 
methods were generally too restrictive to detect certain phenomena that could be biologically 
relevant, such as subtle changes in H3K4 methylation between two stages or conditions. For this 
reason, after our initial screenings we then used the getDifferentialPeaks program within HOMER, 
which probes for peak intensity changes between different conditions. This program allows the user 
to set the fold increase or decrease that must be observed to be considered a differential peak (see 
comments in Table 4). Differential peak analysis performed in this way allowed for the identification 
of things like enhancers that were in the process of being deactivated from PP1 to PP2, but not 
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necessarily completely devoid of H3K27ac at PP2. Table 4 lists the commands and parameters 
used to classify the different groups (G1, G2 and G3) of enhancers and how we identified PP1 
LSD1 peaks near each of the groups. 
 
RNA isolation and sequencing and qRT-PCR 
RNA was isolated from cell samples using the RNeasy® Micro Kit (Qiagen) according to 
the manufacturer instructions. For each cell stage and condition analyzed between 0.1 and 1 x 106 
cells were collected for RNA extraction. For qRT-PCR, cDNA synthesis was first performed using 
the iScript™ cDNA Synthesis Kit (Bio-Rad) and 500 ng of isolated RNA per reaction. qRT-PCR 
reactions were performed in triplicate with 10 ng of template cDNA per reaction using a CFX96™ 
Real-Time PCR Detection System and the iQ™ SYBR® Green Supermix (Bio-Rad). PCR of the 
TATA binding protein (TBP) coding sequence was used as an internal control and relative 
expression was quantified via double delta CT analysis. For RNA sequencing (RNA-seq), stranded, 
single-end sequencing libraries were constructed from isolated RNA using the TruSeq® Stranded 
mRNA Library Prep Kit (Illumina®) and library sequencing was performed on a HiSeq 4000 System 
(Illumina®). Both library construction and sequencing were performed by the IGM core research 
facility at UCSD. Sequence files were mapped to the human genome (hg19/GRCh37) using the 
Spliced Transcripts Alignment to a Reference (STAR) aligner (Dobin, Davis et al. 2013). Tag 
directories were constructed from STAR outputs and normalized gene expression (fragments per 
kilobase per million mapped reads; FPKM) for each sequence file were determined using HOMER 
(Heinz, Benner et al. 2010). HOMER was used to annotate all RefSeq genes with FPKM values 
and to invoke the R packages edgeR (Robinson, McCarthy et al. 2010, McCarthy, Chen et al. 2012) 
and DESeq2 (Love, Huber et al. 2014) for various differential expression analyses. At least two 
biological replicates (n = 2) were analyzed for every stage and condition unless noted otherwise. 
For k-means clustering, normalized FPKM values for each gene were normalized to the time point 
with maximum expression, which was set to 1. This generated a table of genes with values ranging 
from 0 to 1 across the GT to PP1 to PP2 time course. Data transformed in this manner was used 
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to generate heatmaps as well as for k-means clustering. K-means clustering was performed in R 
to identify groups of genes with similar expression patterns across the time course, regardless of 
absolute expression values. 8 clusters were requested and clustering was performed starting from 
random points in the data (100 iterations). This was repeated over 10 times to ensure the same 
genes were reproducibly clustered together. 
Primers used for RT-qPCR are as follows: 
INS-F: 5’-AAGAGGCCATCAAGCAGATCA  
INS-R: 5’-CAGGAGGCGCATCCACA  
GCG-F: 5’-AAGCATTTACTTTGTGGCTGGATT  
GCG-R: 5’-TGATCTGGATTTCTCCTCTGTGTCT  
HOXA1-F: 5’-CGGAACTGGAGAAGGAGTTC 
HOXA1-R: 5’-TTCACTTGGGTCTCGTTGAG 
SST-F: 5’-CCCCAGACTCCGTCAGTTTC 
SST-R: 5’-TCCGTCTGGTTGGGTTCAG 
TBP-F: 5’-ATTAAGGGAGGGAGTGGCAC 
TBP-R: 5’-GCTTTGCTTCCCTTTCCCAA 
 
Assignment of enhancer target genes and Motif enrichment analysis 
Target genes were assigned using the Genomic Regions Enrichment of Annotations Tool 
(GREAT) (http://bejerano.stanford.edu/great/public/html/; (McLean, Bristor et al. 2010), using the 
following parameters: basal plus extension, 5kb upstream, 1kb downstream and plus distal 200kb 
regions. HOMER (Heinz, Benner et al. 2010) was used to identify transcription factor (TF) binding 
motifs enriched in the G1 enhancer group over the G2 and G3 groups. G2 and G3 enhancer peak 
files were merged and set as the background using the appropriate option in the 
findMotifsGenome.pl program. G1 enhancers associated with one or more genes with FPKM ≥ 1 
at the PP1 stage were used for motif analysis. 
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Immunofluorescence analysis. 
Cell aggregates derived from hESCs were allowed to settle in microcentrifuge tubes and 
washed twice with PBS before fixation with 4% paraformaldehyde for 30 min at room temperature. 
Fixed cells were washed twice with PBS and incubated overnight at 4 °C in 30% (w/v) sucrose in 
PBS. Cell aggregates were then loaded into disposable embedding molds (VWR), covered in 
Tissue-Tek® O.C.T. Sakura® Finetek compound (VWR) and flash frozen on dry ice to prepare 
frozen blocks. The blocks were sectioned at 10 µm and sections were placed on Superfrost Plus® 
(Thermo Fisher) microscope slides and washed with PBS for 10 min. Slide-mounted cell sections 
were permeabilized and blocked with blocking buffer, consisting of 0.15% (v/v) Triton X-100 
(Sigma) and 1% (v/v) normal donkey serum (Jackson Immuno Research Laboratories) in PBS, for 
1 hour at room temperature. Slides were then incubated overnight at 4 °C with primary antibody 
solutions. The following day slides were washed five times with PBS and incubated for 1 hour at 
room temperature with secondary antibody solutions. Cells were washed five times with PBS before 
coverslips were applied. All antibodies were diluted in blocking buffer at the ratios indicated below. 
Primary antibodies used were: sheep anti-NGN3 (1:300, R&D Systems); rabbit anti-SOX9 (1:1000 
dilution, Millipore); goat anti-PDX1 (1:500 dilution, Abcam); mouse anti-NKX6.1 (1:300 dilution, 
Developmental Studies Hybridoma Bank); rabbit anti-CHGA (1:1000, DAKO); guinea pig anti-
INS(1:500, DAKO), mouse anti-GCG (1:500, Sigma), rabbit anti-SST (1:500, DAKO). Secondary 
antibodies against sheep, rabbit, goat, mouse and guinea pig were Alexa488-, Cy3- and Cy5-
conjugated donkey antibodies and were used at dilutions of 1:1000, 1:2000, and 1:250, respectively 
(Jackson Immuno Research Laboratories). Representative images were obtained with a Zeiss 
Axio-Observer-Z1 microscope equipped with a Zeiss ApoTome and AxioCam digital camera. 
Figures were prepared in Adobe Creative Suite 5. 
 
Human tissue 
 Human fetal pancreas donor tissue was obtained from the Birth Defects Research 
Laboratory of the University of Washington. Cadaveric adult pancreata used in this study were from 
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non-diabetic donors and were acquired through the Network for Pancreatic Organ Donors with 
Diabetes (nPOD) (Campbell-Thompson, Wasserfall et al. 2012). Protein expression was analyzed 
in nPOD donors: LSD1 and GCG in #6140 (38 year old male); LSD1 and CHGA in #6160 (22 year 
old male); LSD1 and SST in 6178 (25 year old female); and LSD1, INS and GCG in 6179 (21 year 
old female). 
 
Mice 
 Pdx1-Cre, Pdx1-CreERTM (Gu, Dubauskaite et al. 2002) and Lsd1flox (Wang, Scully et al. 
2007) mouse strains have been described previously. Lsd1Δpan knockouts were generated by 
crossing Pdx1-Cre and Lsd1flox mice. Conditional Lsd1 knockouts were generated by crossing 
Pdx1-CreERTM and Lsd1flox mice. Tamoxifen (Sigma) was dissolved in corn oil (Sigma) at 10 
mg/mL, and a single dose of 3.5 mg/40 g or 4.5 mg/40 g body weight was administered by 
intraperitoneal injection at embryonic day (e) 10.5 or e12.5, respectively. Control mice were LSD1+/+ 
littermates carrying Pdx1-Cre transgene. Midday on the day of vaginal plug appearance was 
considered e0.5. 
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FIGURES 
 
Figure 1. Endocrine cell formation requires LSD1 activity during a short window in early pancreatic 
development.  
 
(A) Immunofluorescent staining of pancreatic sections for LSD1 with the pancreatic progenitor 
markers PDX1 and SOX9 (55 days post-conception (dpc) fetal pancreas) or the pan-endocrine 
marker chromogranin A (CHGA) (94 dpc and adult pancreas). Scale bar, 50 µm. 
(B) Schematic of the human embryonic stem cell (hESC) differentiation protocol to the endocrine 
cell stage (EN) and experimental plan for LSD1 inhibition. 
(C) Immunofluorescent staining for pancreatic hormones insulin (INS), glucagon (GCG) and 
somatostatin (SST) or PDX1 and NKX6.1 in control EN cells compared to EN cells with early 
(LSD1iearly) and late (LSD1ilate) LSD1 inhibition. Scale bar, 50 µm. 
(D) qRT-PCR analysis for INS, GCG and SST in control, LSD1iearly and LSD1ilate EN cells. Data are 
shown as mean ± S.E.M (n = 2 biological replicates). *p < 0.001. 
(E) Flow cytometry analysis at EN stage for NKX6.1, PDX1 and INS comparing control, LSD1iearly 
and LSD1ilate cells. Isotype control for each antibody is shown in red and target protein staining in 
green. Percentage of cells expressing each protein is indicated. 
AA, activin A; ITS, insulin-transferrin-selenium; TGFBi, TGFβ R1 kinase inhibitor; KGF, 
keratinocyte growth factor; RA, retinoic acid; EGF, epidermal growth factor; ES, embryonic stem 
cell; DE, definitive endoderm; GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late 
pancreatic progenitors; EN, endocrine cell stage; FSC-A, forward scatter area. 
See also Figure S1. 
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Figure 2. LSD1 inhibition prevents decommissioning of transiently active early pancreatic 
enhancers. 
 
(A) Heatmap showing density of ChIP-seq reads for LSD1 and H3K27ac centered on LSD1 peaks, 
spanning 10 kb. G1, G2 and G3 groups of LSD1-bound enhancers are deactivated (G1), remain 
active (G2), or are deactivated (G3) from PP1 to PP2. 
(B) Tag density plots displaying LSD1 tag distribution at G1, G2 and G3 enhancers at PP1 and 
PP2 stages, centered on PP1 LSD1 peaks. 
(C) Box plots of H3K4me1 and H3K4me2 ChIP-seq counts at G1, G2 and G3 enhancers at PP1 
and PP2 stages. *p < 0.05; **p < 5e-12; *** < 2.2e-16. 
(D) Tag density plots for G1 enhancers displaying H3K27ac, H3K4me2 and H3K4me1 tag 
distribution at PP1 stage and PP2 stage with and without early LSD1 inhibition (LSD1iearly). Plots 
are centered on PP1 LSD1 peaks.  
(E) Model for LSD1-dependent enhancer decommissioning. Enhancer deactivation by removal of 
acetylation from H3K27 occurs independent of LSD1 activity. LSD1 subsequently mediates 
enhancer decommissioning by removal of H3K4me2 marks. 
PP1, early pancreatic progenitors; PP2, late pancreatic progenitors. 
See also Figure S2 and Tables S1-S6. 
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Figure 3. LSD1 activity is necessary for down-regulation of transiently expressed retinoic acid-
dependent genes.  
 
(A) Enriched transcription factor (TF) binding motifs with associated p-values for G1 enhancers 
compared to G2 and G3 enhancers.  
(B) Percentage of G1 enhancers versus random genomic regions bound by RXR within ± 10kb of 
LSD1 peak at the PP1 stage. **p < 2.5e-8, chi-square.  
(C) Schematic showing timing and duration of retinoic acid (RA) addition (top) and coincident 
changes in H3K27ac levels at RXR-bound G1 enhancers (bottom) during hESC differentiation 
toward endocrine (EN) cells with and without LSD1 inhibition from PP1 to PP2 (LSD1iearly). ***p < 
2.2e-16, Wilcoxon. 
(D) K-means clustering of genes associated with RXR-bound G1 enhancers (Table 2) based on 
mRNA expression (FPKM) (n=3). Genes were assigned to enhancers using the Genomic Regions 
Enrichment of Annotations Tool (GREAT) within a 200kb window. mRNA levels shown as relative 
to maximum per gene across time course. Yellow box highlights gene cluster exhibiting RA-
dependent (PP1-specific) expression pattern. 
(E) Heatmap of gene expression for PP1-specific genes associated with RXR-bound G1 enhancers 
across GT, PP1, and PP2 (n=74) with and without LSD1 inhibition (LSD1iearly). Gene set defined 
by FPKM at PP1 ≥ 1 and PP1 mRNA levels ≥ 2-fold compared to GT and PP2. mRNA levels 
(FPKM) shown as relative to maximum per gene across time course. 
(F) Box plots of mRNA levels for genes shown in E. *p < 0.005, Wilcoxon. 
(G) LSD1, RXR, H3K4me2, and H3K27ac ChIP-seq profiles at enhancers near HOXA1 and 
HOXC4. 
GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic progenitors. 
See also Figure S3 and Tables 1-3. 
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Figure 4. Prolonged retinoic acid exposure of early pancreatic progenitor cells phenocopies LSD1 
inhibition. 
 
(A) Experimental plan to extend retinoic acid (RA) exposure through the PP1 to PP2 transition 
(RAextended) during hESC differentiation to the endocrine cell stage (EN). 
(B) Heatmap of gene expression for the 74 PP1-specific genes associated with RXR-bound G1 
enhancers (Table 3) at PP2 with and without extended RA treatment (RAextended). 
(C) Relative normalized expression of select genes from group in (B) at PP2 with and without 
extended RA treatment (RAextended). Data shown as mean ± S.E.M. relative to control values (blue 
bars), which were set to 1. *p < 0.05; **p < 0.0005, DESeq2 output. 
(D) Immunofluorescent staining for insulin (INS), glucagon (GCG) and somatostatin (SST) in control 
EN cells compared to EN cells with extended RA treatment (RAextended). Scale bar, 50 µm. 
(E) Flow cytometry analysis at EN stage for NKX6.1, PDX1 and INS comparing control and 
RAextended cultures. Isotype control for each antibody is shown in red and target protein staining 
in green. Percentage of cells expressing each protein is indicated. 
GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic progenitors. 
See also Figure S4. 
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Figure 5. LSD1 prevents aberrant reactivation of transient early retinoic acid-dependent genes. 
 
(A) Experimental plan to re-introduce retinoic acid (RA) during the PP2 to endocrine (EN) transition 
(RAlate) of hESC differentiation. 
(B) Immunofluorescent staining for insulin (INS), glucagon (GCG) and somatostatin (SST) in control 
EN cells compared to EN cells with late RA treatment (RAlate). Scale bar, 50 µm. 
(C) Flow cytometry analysis at EN stage for NKX6.1, PDX1 and INS comparing control and RAlate 
cells. Isotype control for each antibody is shown in red and target protein staining in green. 
Percentage of cells expressing each protein is indicated. 
(D) Heatmap of gene expression for the 74 PP1-specific genes associated with RXR-bound G1 
enhancers (Table 3) at EN stage with and without late RA treatment (RAlate). 
(E) Relative normalized expression of select genes from group in (D) at EN stage with and without 
late RA treatment (RAlate). Data shown as mean ± S.E.M. relative to control values (blue bars), 
which were set to 1. n.s., not significant; DESeq2 output. 
(F) Experimental plan to re-introduce RA during the PP2 to EN transition (RAlate) after early 
inhibition of LSD1 (LSD1iearly). 
(G) Immunofluorescent staining for INS, GCG and SST in control EN cells compared to LSD1iearly 
EN cells with and without late RA treatment (RAlate). Scale bar, 50 µm. 
(H) Heatmap of gene expression for the 74 PP1-specific genes associated with RXR-bound G1 
enhancers (Table 3) at EN stage with LSD1iearly alone and LSD1iearly plus late RA treatment 
(RAlate). 
(I) Relative normalized expression of select genes from group in (H) at EN stage with LSD1iearly 
alone and LSD1iearly plus late RA treatment (RAlate). Data shown as mean ± S.E.M. relative to 
LSD1iearly values (blue bars), which were set to 1. *p < 0.05; **p <0.005, ***p < 1e-17. DESeq2 
output. 
GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic progenitors. 
See also Figure S5. 
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Figure 6. Selective requirement for Lsd1 in endocrine cell formation during a short window in early 
pancreatic development of mice. 
 
(A) Strategy for conditional Lsd1 deletion in embryonic pancreatic progenitors of mice (Lsd1Δpan). 
Yellow boxes: exons; green triangles: loxP sites. 
(B) Immunofluorescent staining for Pdx1 at embryonic day (e) 12.5 and Lsd1, insulin (Ins) and 
glucagon (Gcg) at postnatal day (P) 0 in control and Lsd1Δpan mice. Boxed areas are shown in 
higher magnification. Scale bar, 50 µm. 
(C) Quantification of pancreatic epithelial area at e12.5 and e15.5. Data shown as means ± SEM 
(n = 3 biological replicates). n.s., not significant, Student t-test. 
(D) Immunofluorescent staining for Ins with somatostatin (Sst), pancreatic polypeptide (Ppy) and 
ghrelin (Ghrl) at P0 in control and Lsd1Δpan mice. Scale bar, 25 µm. 
(E) Strategy for tamoxifen-inducible Lsd1 deletion in embryonic pancreatic progenitors of mice at 
e10.5 (Lsd1Δearly) and e12.5 (Lsd1Δlate). Yellow boxes: exons; green triangles: loxP sites. 
(F) Immunofluorescent staining for Lsd1, Ins and Gcg at e18.5 in control, Lsd1Δearly and Lsd1Δlate 
mice. Boxed areas are shown in higher magnification. Scale bar, 50 µm. 
(G) Heatmap of gene expression in dissected pancreata from control and Lsd1Δpan mice at e13.5. 
Shown are PP1-specific genes associated with RXR-bound G1 enhancers (Table 3). 
(H) Relative normalized expression of select genes from group in (G) in Lsd1Δpan mice at e13.5. 
Data shown as mean ± S.E.M. relative to control values (blue bars), which were set to 1. *p < 0.05; 
**p < 0.01; **p < 5e-5; n.s., not significant, DESeq2 output. 
See also Figure S6. 
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Figure S1. Related to Figure 1. Characterization of LSD1 expression and effects of LSD1 inhibition 
on pancreatic progenitor cells.  
 
(A) Immunofluorescent staining for LSD1 with insulin (INS), glucagon (GCG) and somatostatin 
(SST) in adult human pancreas. Scale bar, 10 µm. 
(B) LSD1 mRNA expression at each stage of differentiation determined by RNA-seq, measured in 
fragments per kilobase per million fragments mapped (FPKM). Values shown as log2(FPKM). 
(C) Immunofluorescent staining for LSD1 at each stage of hESC differentiation. Scale bar, 25 µm. 
(D) Immunofluorescent staining for NKX6.1 and PDX1 in control and LSD1iearly PP2 cells. Scale 
bar, 50 µm. 
(E) Flow cytometry analysis for NKX6.1 and PDX1 comparing control and LSD1iearly PP2 cells. 
ES, embryonic stem cell; DE, definitive endoderm; GT, primitive gut tube; PP1, early pancreatic 
progenitors; PP2, late pancreatic progenitors; EN, endocrine cell stage; FSC-A, forward scatter 
area. 
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Figure S2. Related to Figure 2. Characterization of LSD1-bound genomics regions. 
 
(A) LSD1 peak localization across the genome relative to transcriptional start sites (TSSs). 15,084 
total LSD1 peaks identified in PP1. 3,285 peaks are proximal (within 3kb of a TSS) and 11,799 
distal (> 3kb from a TSS).  
(B) Tag density plots for G2 and G3 enhancers displaying H3K27ac, H3K4me2 and H3K4me1 tag 
distribution at P1 stage and PP2 stage with and without early LSD1 inhibition (LSD1iearly). Plots are 
centered on PP1 LSD1 peaks. 
UTR, untranslated region; TTS, transcription termination site; ncRNA, non-coding RNA; PP1, early 
pancreatic progenitors; PP2, late pancreatic progenitors. 
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Figure S3. Related to Figure 3. G1 enhancers exhibit greater enrichment for RXR binding than G2 
and G3 enhancers. 
 
(A) Percentage of G1, G2 and G3 enhancers versus random genomic regions bound by RXR within 
± 10kb of LSD1 peak at the PP1 stage. Significantly higher enrichment in G1 enhancers than in G2 
and G3 enhancers. **p < 5e-4, chi-square. 
(B) Changes in H3K4me1 and H3K4me2 levels at RXR-bound G1 enhancers during human 
embryonic stem cell differentiation with and without LSD1 inhibition (LSD1iearly). *p < 0.005; ***p < 
2.2e-16; n.s., not significant, Wilcoxon. 
(C) Relative normalized gene expression at the PP2 stage with and without early LSD1 inhibition 
(LSD1iearly). Genes were selected from group of 74 genes exhibiting RA-dependent expression (Fig. 
3E; Table 3). Data shown as mean ± S.E.M. relative to control values (blue bars), which were set 
to 1. *p < 0.005; **p < 5e-4, DESeq2 output. 
(D) LSD1, RXR, H3K4me2, and H3K27ac ChIP-seq profiles at enhancers near GATA4 and 
DHRS3.  
GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic progenitors. 
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Figure S4. Related to Figure 4. Effects of prolonged retinoic acid treatment on pancreatic 
progenitor and endocrine cell phenotypes.  
 
(A) Box plot of mRNA levels for genes exhibiting retinoic acid (RA)-dependent pattern (Table 3) 
comparing control and RAextended PP2 cells. *p < 0.01, Wilcoxon. 
(B) qRT-PCR analysis for insulin (INS), glucagon (GCG) and somatostatin (SST) in control and 
RAextended EN cells. Data are shown as average ± S.E.M (n = 2 biological replicates). **p < 0.001, 
Student t-test. 
(C) Immunofluorescent staining for PDX1 and NKX6.1 in control endocrine stage cells (EN) 
compared to EN cells with extended RA treatment (RAextended). Scale bar, 50 µm. 
GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic progenitors. 
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Figure S5. Related to Figure 5. Effects of re-introducing retinoic acid during endocrine cell 
differentiation with and without prior LSD1 inhibition.  
 
(A) Immunofluorescent staining for PDX1 and NKX6.1 in control endocrine stage cells (EN) 
compared to EN cells with late retinoic acid (RA) treatment (RAlate). Scale bar, 50 µm. 
(B) qRT-PCR analysis for INS, GCG and SST in control and RAlate EN cells. Data are shown as 
average ± S.E.M (n = 2 biological replicates). 
(C) Box plot of mRNA levels for genes exhibiting RA-dependent pattern (Table 3) comparing control 
and RAlate EN cells. n.s., not significant. 
(D) Flow cytometry analysis at EN stage for NKX6.1, PDX1 and INS comparing control EN cells to 
LSD1iearly EN cells with and without late RA treatment (RAlate). Isotype control for each antibody is 
shown in red and target protein staining in green. Percentage of cells expressing each protein is 
indicated. 
(E) Box plot of mRNA levels for genes exhibiting RA-dependent pattern (Table 3) comparing EN 
cells treated with LSD1iearly alone and LSD1iearly plus RAlate. *p < 0.005, Wilcoxon. 
(F) Tag density plots displaying RXR tag distribution at RXR-bound G1 enhancers at the PP1 stage 
and PP2 stage with and without LSD1 inhibition (LSD1iearly). Plots are centered on PP1 LSD1 
peaks. 
GT, primitive gut tube; PP1, early pancreatic progenitors; PP2, late pancreatic progenitors; EN, 
endocrine stage; FSC-A, forward scatter area. 
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Figure S6. Related to Figure 6. Phenotypic characterization of Lsd1Δpan mice. 
 
(A) Immunofluorescent staining of embryonic (e) and neonatal (P0) mouse pancreas for Lsd1 with 
the pancreatic progenitor markers Pdx1 and Sox9, the acinar marker carboxypeptidase 1 (Cpa1) 
or insulin (Ins) and glucagon (Gcg). Boxed areas are shown in higher magnification. Scale bar, 50 
µm. 
(B) Immunofluorescent staining for Lsd1 with Ins, Gcg and Sst in mice at P0. Scale bar, 10 µm. 
(C) Immunofluorescent staining of pancreas (Pan) from control and Lsd1Δpan embryos for Lsd1, 
Ptf1a, Nkx6.1, phospho histone H3 (pHH3), Pdx1, E-cadherin (Cdh1), osteopontin (Opn), amylase 
(Amy), and TUNEL. The nuclear counterstain, 4′,6-diamidino-2-phenylindole (DAPI) is shown 
together with TUNEL staining. Scale bar, 50 µm. 
(D) Quantification of pHH3+ cells at e12.5 and apoptotic cells (TUNEL+) at e15.5 relative to 
pancreatic epithelial area. Data are shown means ± SEM (n = 3 biological replicates). n.s, not 
significant, Student t-test. 
(E) Quantification of hormone+ cells staining positive for Lsd1 in control, Lsd1Δpan, Lsd1Δearly, and 
Lsd1Δlate mice at P0. A total of 189-1057 hormone+ cells (insulin+ or glucagon+) were analyzed per 
genotype and set as 100% (n = 3 per genotype). 
(F) Box plots of mRNA levels in mouse pancreas for PP1-specific genes associated with RXR-
bound G1 enhancers (Table 3). Relative gene expression determined by microarray analysis of 
sorted Sox9+ pancreatic progenitor cells at e10.5 and e15.5 (left). Gene expression determined by 
RNA-seq of dissected pancreata from control and Lsd1Δpan mice at e13.5 (right) ( n = 3 biological 
replicates). 
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TABLES 
Table 1. Chromosomal coordinates of 612 RXR-bound G1 enhancers identified in the early 
pancreatic progenitor (PP1) stage of pancreatic differentiation of hESCs. 
 
 
55 
Table 2. 634 genes associated with RXR-bound G1 enhancers. Associated PeakID(s) and their 
distances from the nearest TSS are provided. Genes were assigned using GREAT version 3.0.0 
(McLean, Bristor et al. 2010). Species assembly: hg19. Association rule: Basal+extension: 5000 
bp upstream, 1000 bp downstream, 200000 bp max extension, curated regulatory domains 
included. 
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Table 3. Subset of 74 genes from the 634 genes associated with RXR-bound G1 enhancers. That 
exhibited RA-dependent gene expression patterns across the gut tube (GT), early (PP1) and late 
(PP2) pancreatic progenitor stages of pancreatic differentiation of hESCs. 
 
 
  
ABCA8 DHRS3 GLT8D2 MKRN3 RNF182
ADM DNAH7 GPR37L1 MUC20 ROS1
AGO1 DUSP9 HMCN1 MYOF SHH
ANO1 EHF HOXA1 NEDD4L SLC6A12
ASTN1 ELF3 HOXB1 NR2F2 SMOC1
ATP10B EPHB3 HOXC4 PAQR7 STC2
B4GALNT3ETS2 HSD17B14PBX1 TMC6
C8orf49 FAM129A IQGAP2 PLTP TMEM110
CADM3 FANCE ITGA11 POPDC3 TMEM44
CDC42EP3FOXA1 ITGA6 PPARD TRABD2B
CDHR3 GADD45GITPR3 PRKAB2 TTC30A
CHST15 GADL1 KCNJ4 PRKCDBPVEGFA
CLIC6 GATA4 LNX1 PRR15 VILL
COLGALT2GFRA1 LYST PTGIS ZNF703
CSF3R GIP MECOM RARB
Gene Names
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Table 4. Example commands and software packages used for ChIP- and RNA-seq data analysis 
workflow. 
Command Comments Software 
package 
bowtie2 -t --very-sensitive -x 
<hg19> input.fastq > output.sam 
Map ChIP-seq data to the human genome. 
The option "--very-sensitive" sets multiple 
parameters. Specifically, it is equivalent to 
setting all the following options: 
-D 20 -R 3 -N 0 -L 20 -i S,1,0.50 
Bowtie 2 
v2.2.7 
samtools view -bhu output.sam > 
output.bam 
Convert SAM file format to BAM in order to 
sort. 
Samtools 
v1.3.1 
samtools sort output.bam > 
sorted_output.bam Sort BAM file in order to remove duplicates. 
Samtools 
v1.3.1 
samtools rmdup -s 
sorted_output.bam 
rmdup_output.bam 
Remove exact duplicate read sequences. Samtools v1.3.1 
makeTagDirectory 
rmdup_output_tagDir/ 
rmdup_output.bam -genome hg19 -
checkGC 
Generate tag directories for downstream 
analyses and analyze GC content of 
sequencing results. 
HOMER 
v4.9 
makeUCSCfile 
rmdup_output_tagDir/ -o auto -
bigWig ~/chrom.sizes -fsize 1e20 > 
rmdup_output.trackInfo.txt 
Generate a file for data visualization on a 
genome browser. 
HOMER 
v4.9 
getDifferentialPeaks 
PP1_H3K27ac_regions 
PP1_H3K27ac_tag_directory/ 
PP1_H3K27ac_tag_directory/ -F 2 
Uses tag directories to analyze for 
differential peak intensity between samples. 
The -F 2 option designates >= 2-fold 
difference in peak intensity is a considered 
differential peak. 
HOMER 
v4.9 
windowBed -a 
distal_PP1_LSD1_peaks -b 
deactivating_enhancers_PP1_to_P
P2 -w 1000 -u 
Identify peaks in file “-a” that are near 
peaks/regions from file “-b”. 
The -w 1000 option looks for overlap ± 1000 
bp of the peak. 
Bedtools 
v2.17.0 
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CHAPTER 2 - DISSECTING THE ROLE OF NEUROGENIN-3 IN HUMAN ENDOCRINE 
DEVELOPMENT 
 
ABSTRACT 
Diabetes mellitus is a widespread pancreatic disease that is characterized by the loss or 
dysfunction of insulin-producing beta-cells. One method of treating diabetes is the transplantation 
of beta cells from cadaver donors to diabetic patients. However, the lack of donor material and the 
need for lifelong immunosuppression has precluded widespread use of this therapy. Generation of 
functional beta-cells from human embryonic stem cells (hESCs) would not only provide an attractive 
and renewable cell-replacement therapy, but would also greatly increase our ability to understand 
human pancreas endocrine development and the pathogenesis of related diseases. Current in vitro 
pancreatic differentiation protocols exist that can generate properly specified hESC-derived 
pancreatic progenitors which are capable of becoming functional beta-cells in vivo after 
engraftment into mice. Recent advances in the field have progressed the state of the art such that 
functional, glucose-responsive, insulin-secreting cells can now be generated entirely in vitro. 
However, these hESC-derived beta cells often secrete low levels of insulin in a manner that is 
reminiscent of immature fetal beta cells (Russ, Sintov et al. 2011, Pagliuca, Millman et al. 2014, 
Rezania, Bruin et al. 2014). Moreover, the time required to reach this stage, beginning from the 
hESC state, can be a month or longer (Russ, Sintov et al. 2011, Pagliuca, Millman et al. 2014, 
Rezania, Bruin et al. 2014). Thus, as they exist now, these cells are not yet suitable as beta-cell 
replacements. While this shows it is possible to make beta-cells from hESCs, there remains a great 
desire to more rapidly produce fully functional and mature beta-cells entirely in vitro. Understanding 
the events that dictate cell fate decisions during pancreas development is critical to improving 
current protocols to rapidly generate functional beta cells in vitro. To achieve this goal, a greater 
understanding of the transcriptional events that specify proper human endocrine formation is 
required. 
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INTRODUCTION 
The pancreas is a vital organ composed of three main compartments: acinar, ductal and 
endocrine. The endocrine cells are localized together forming the islets of Langerhans. Within these 
islets are five endocrine cell subtypes: alpha, beta, delta, epsilon and PP cells, which produce the 
hormones glucagon, insulin, somatostatin, ghrelin and pancreatic polypeptide, respectively (Shih, 
Wang et al. 2013). The insulin-producing beta cells are responsible for maintaining blood glucose 
homeostasis and their dysfunction results in diabetes. The need for better treatments and 
understanding of this incredibly prevalent disease has instigated a massive effort to generate beta 
cells in vitro (Schulz 2015). The many advances that have been made in the development of in 
vitro pancreatic differentiation protocols have been inspired by lessons learned from the mouse. 
During early murine development, the pancreas emerges from the early embryonic structure called 
the posterior foregut (Seymour and Sander 2011, Shih, Wang et al. 2013). At this stage the nascent 
pancreatic buds consist entirely of multipotent progenitor cells (MPCs) marked by the transcription 
factors PDX1, SOX9, PTF1A and NKX6.1 (Seymour and Sander 2011, Arda, Benitez et al. 2013, 
Shih, Wang et al. 2013). These MPC’s subsequently undergo a series of morphogenetic changes 
and cell fate decisions which result in generation of the diverse cell types and complex structure of 
the mature pancreas. The first fate decision undergone by MPCs determines whether the cells will 
be restricted to the tip domain (acinar cells) or trunk domain (ductal and endocrine cells). The 
transcription factors PTF1A and NKX6.1 act as master regulators of this decision, where PTF1A 
specifies tip identity, while NKX6.1 specifies trunk identity. Although they are co-expressed in early 
MPCs, mutual repression between PTF1A and NKX6.1 ensures complete segregation of the two 
domains giving rise to PTF1A+ acinar cells and NKX6.1+ bipotent trunk progenitors (Schaffer, 
Freude et al. 2010, Shih, Wang et al. 2013). These trunk progenitors can become either ductal or 
endocrine cells. The basic helix-loop-helix transcription factor neurogenin-3 (NGN3) is the major 
driver of the endocrine cell fate. In mice, deletion of Ngn3 results in a total absence of endocrine 
cells, whereas ectopic expression in early MPCs induces premature differentiation to endocrine 
cells (Gradwohl, Dierich et al. 2000, Johansson, Dursun et al. 2007). Ngn3 is expressed for a short 
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time window in a subset of the bipotent trunk progenitors, during which it initiates cell-cycle exit and 
promotes terminal differentiation toward the endocrine fate (Schwitzgebel, Scheel et al. 2000, Gu, 
Dubauskaite et al. 2002, Gasa, Mrejen et al. 2004, Rukstalis and Habener 2009). Immunohistology 
of human embryonic tissue shows NGN3 follows a similar expression pattern to that observed in 
mice. Therefore, it is widely believed that NGN3 plays the same role in humans as it does in mice. 
However, studies of NGN3 mutations, identified in non-diabetic humans, have raised some 
controversy over whether NGN3 is strictly required for human endocrine development. 
In addition to the requirement of Ngn3 for endocrine development in mice, the timing of its 
expression is critical for proper development of endocrine subtypes. Genetic experiments in mice 
have shown that premature expression of Ngn3 in the developing embryo results in the production 
of polyhormonal endocrine cells (Apelqvist, Li et al. 1999, Schwitzgebel, Scheel et al. 2000, 
Johansson, Dursun et al. 2007). In addition, through slight alterations of the timing of Ngn3 
expression during development in a Ngn3-null background, it was shown that different endocrine 
subtypes were produced depending on when Ngn3 was expressed (Johansson, Dursun et al. 
2007). For example, when Ngn3 was reconstituted at a time prior to the onset of endogenous Ngn3 
expression the majority of cells formed were glucagon+ (Johansson, Dursun et al. 2007). While 
many of these cells appeared to be normal alpha cells, a large proportion (~30%) co-expressed 
hormones other than glucagon. Conversely, when Ngn3 was reconstituted at a time coincident with 
endogenous Ngn3 expression, the majority of cells formed were insulin+. In this case, the insulin+ 
cells obtained were fully functional beta cells, virtually indistinguishable from wild-type beta cells. 
Moreover, there was a complete absence of any polyhormonal cells in the resulting endocrine 
population. These studies indicate that the timing of Ngn3 expression is crucial not only for proper 
endocrine differentiation, but also in determining the subtype of endocrine cells produced. 
Our lab employed a step-wise hESC differentiation protocol that mimics early endodermal 
and pancreatic development as shown by the correct induction of specific pancreatic markers, such 
as PDX1. This protocol reliably and efficiently generates pancreatic progenitors and endocrine cells 
in vitro. The resulting pancreatic progenitors are functional, as they are capable of further 
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differentiating into functional beta cells in vivo, following implantation into mice for 3-4 months 
(D'Amour, Bang et al. 2006, Kroon, Martinson et al. 2008, Schulz, Young et al. 2012). At the time 
of this study, however, the in vitro-derived endocrine cells were non-functional, characterized by 
the expression of multiple hormones, lack of true beta cell markers (NKX6.1, PDX1, MAFA), and 
the inability to secrete insulin in response to glucose stimulation. These endocrine cells are 
strikingly similar to the polyhormonal cells that result from early expression of Ngn3 in the 
aforementioned mice studies (Johansson, Dursun et al. 2007). Perhaps unsurprisingly, NGN3 is 
expressed too early during in vitro differentiation, preceding the appearance of the trunk progenitor 
markers SOX9, PDX1 and NKX6.1d. Based on mouse studies as well as our own observations, 
we hypothesized that this premature expression of NGN3, during the in vitro differentiation, induces 
endocrine formation in cells that have not been properly restricted to one subtype, causing them to 
express multiple hormones. Furthermore, we speculated that suppression of NGN3 expression 
until after the emergence of pancreatic progenitors could provide the cells sufficient time to become 
restricted to a single potential subtype. In this study, we examined the results of forced 
misexpression of NGN3 during pancreatic differentiation of human embryonic stem cells. Using 
lentiviral overexpression and shRNA knockdown strategies, we studied the role of NGN3 
expression in pancreatic progenitors and demonstrated that NGN3 knockdown prevents endocrine 
formation while its overexpression induces differentiation to the endocrine stage. Our results 
provide direct evidence that, as in mice, NGN3 expression is necessary and sufficient for endocrine 
specification in human cells. 
 
RESULTS 
Knockdown of NGN3 in hESCs results in a decrease of endocrine cells. 
To study human pancreatic endocrine development, our lab uses a step-wise differentiation 
protocol in which hESCs are aggregated in non-adherent conditions and differentiated to pancreatic 
progenitors and polyhormonal endocrine cells. These non-functional endocrine cells typically 
emerge by D13, which marks the end of the differentiation (Figure 7A). To determine whether 
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NGN3 is necessary for endocrine specification in our hESC differentiation system, we performed 
specific knockdown of NGN3 in hESCs using lentiviral short hairpin RNAs (shRNAs). To do this, 
we used four lentiviral constructs, each containing a constitutively expressed shRNA sequence 
targeting a different region of the endogenous human NGN3 transcript. Lentiviruses were 
constructed using our 2nd generation lentiviral assembly protocol and hESCs were transduced with 
a mixture of the four viruses. A scrambled shRNA construct was used to generate cell lines to be 
used as a negative control. A puromycin resistance gene within the construct allowed for selection 
of cells that had efficiently integrated the viral payload. Following expansion under puromycin 
selection, cells were passaged into non-adherent culture conditions and prepared for pancreatic 
differentiation. During normal differentiation, endogenous NGN3 expression peaks at day 8 (D8) 
(Figure 7B). Quantitative PCR (qPCR) of both NGN3 knockdown (NGN3 KD) and control cells at 
D8 showed only about a 50% reduction in expression (Figure 8A). Although NGN3 was only 
reduced by half, expression of NEUROD1, a direct target of NGN3, was reduced by about 75%. 
Immunofluorescence and qPCR analysis of D13 NGN3 KD cells showed a drastic reduction of 
insulin and glucagon protein and mRNA levels, respectively (Figure 8B). This finding suggests that 
NGN3 is necessary for human endocrine development. Moreover, nearly all NGN3 KD cells 
expressed pancreatic progenitor markers, suggesting NGN3 is dispensable for progenitor 
formation in vitro (Figure 8C). These observations are in agreement with results from studies of 
Ngn3-/- mice (Gradwohl, Dierich et al. 2000), which showed a complete lack of endocrine cells 
without Ngn3. However, because RNA knockdown did not fully abolish NGN3 expression, and 
endocrine cells were still made, it became clear that a full knockout of NGN3 in hESCs would be 
necessary to conclusively determine its necessity for human endocrine formation. 
 
Overexpression of NGN3 in differentiating cells results in an increase of hormone expression. 
To determine whether NGN3 is sufficient to induce endocrine formation, we constructed a 
lentiviral transfer vector comprised of the human cDNA sequence for NGN3 preceded by the 
constitutive phosphoglycerate kinase (PGK) promoter. An identical construct expressing GFP was 
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used as a control. hESCs were differentiated in aggregate form to D7, dissociated and transduced 
with either the NGN3 overexpression (NGN3 OE) or GFP lentivirus. Cells were allowed to re-
aggregate and differentiation was continued normally to D13. 24 hours after transduction, samples 
were analyzed for expression of NGN3 by qPCR and immunofluorescence. While a robust increase 
in both endogenous and transgenic mRNA was observed, no significant change in NGN3 protein 
levels was detected (Figure 9A and data not shown). 3 days after transduction (D10) NGN3 protein 
expression appeared was slightly increased over controls, while qPCR analysis revealed NGN3 
transcript levels remained much higher than controls (Figure 9A and data not shown). By D13, 
NGN3 mRNA levels were still very high compared to controls, but only a few NGN3+ cells were 
observed by immunofluorescence (Figure 9A and 9B). Analysis of NGN3 OE cells at D10 and D13 
showed little to no increase in insulin and glucagon protein expression, while qPCR showed slightly 
elevated levels of hormone transcripts at D13 (Figure 9B). These results suggest that forced 
expression of NGN3 does not induce endocrine formation. This was most likely due to the lack of 
protein overexpression, despite clearly elevated levels of NGN3 mRNA. 
Due to the discrepancy between mRNA and protein expression, we suspected complex 
regulation of NGN3 was at play. Literature searches revealed abundant biochemical and in vivo 
evidence showing that NGN3, and the related NGN2, are heavily regulated at both the post-
transcriptional and post-translational levels (Vosper, Fiore-Heriche et al. 2007, Vosper, McDowell 
et al. 2009, McDowell, Kucerova et al. 2010, Ali, Hindley et al. 2011, Hindley, Ali et al. 2012). 
Reasoning that the negative regulation of NGN3 might be brought on by its own expression, we 
sought to overexpress NGN3 at a later time to escape this regulation. we therefore overexpressed 
NGN3 at D10, when endogenous NGN3 transcript has largely disappeared (Figure 7B). 3 days 
after transduction (D13) a significant increase in NGN3 protein expression was seen in NGN3 OE 
cells but not in controls (Figure 9C). Insulin and glucagon mRNA levels were drastically increased 
in D13 NGN3 OE cells compared to controls. In addition, immunofluorescence staining showed 
slightly more glucagon+ cells in NGN3 OE conditions compared to controls (Figure 9C). These 
results suggest NGN3 may be sufficient to induce endocrine specification in human cells. 
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 During normal differentiation, a large proportion of cells express pancreatic progenitor 
markers by D10. However, many hormone+ endocrine cells, as well as those destined to become 
endocrine cells, also exist at this stage. This is likely due to the endogenous wave of NGN3 
expression observed around D8. As this endogenous expression preceded the transgenic 
overexpression at D10, it is possible that NGN3 OE simply caused an increase in hormone 
expression in the endocrine/pre-endocrine cells rather than inducing pancreatic progenitors to 
become endocrine cells. In order to conclusively determine if NGN3 is sufficient to drive pancreatic 
progenitors to the endocrine fate, we induced NGN3 overexpression in sorted pancreatic 
progenitors prior to the premature wave of NGN3. 
 
Overexpression of NGN3 in sorted hESC-derived progenitors induces the endocrine fate. 
As previously stated, the in vitro protocol we use generates both pancreatic progenitors 
and polyhormonal endocrine cells. The heterogeneity of the differentiated cells has precluded our 
efforts to determine whether NGN3 can induce endocrine formation from hESC-derived pancreatic 
progenitors. In order to answer this question, we require a method to isolate the progenitors from 
the endocrine cells. Prior research by ViaCyte Inc. identified CD142 and CD200, as cell surface 
markers expressed on pancreatic progenitors or polyhormonal endocrine cells, respectively (Kelly, 
Chan et al. 2011). Fluorescence-activated cell sorting (FACS) using these markers allows for 
efficient separation of the two cell types (Kelly, Chan et al. 2011). Low cell viability following FACS 
precluded ViaCyte Inc.’s efforts to perform transplant experiments with purified progenitors. 
However, by employing a gentler method of magnetic-activated cell sorting (MACS), they showed 
that CD142+ progenitors are capable of becoming functional beta-cells following transplantation, 
while CD200+ endocrine cells are not (Kelly, Chan et al. 2011). We recently optimized a similar 
MACS method for use in our hESC differentiation system allowing for longer cell survival in culture. 
Using the optimized MACS protocol, we were able to isolate a highly pure population of 
CD142+ pancreatic progenitors at D13. To determine if NGN3 expression is sufficient to drive these 
progenitors to the endocrine fate, we transduced them with NGN3 OE lentivirus, re-aggregated the 
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cells and continued culturing them for 9 days (D22). Immunofluorescence analysis showed robust 
NGN3 protein expression that was sustained to D22 (Figure 10A). Additionally, more hormone+ 
cells, marked by the pan-endocrine protein chromogranin A (CHGA), were seen in NGN3 OE cells 
compared to controls (Figure 10A). This result suggests NGN3 expression is sufficient to drive 
endocrine differentiation from pancreatic progenitors. To assess whether forced NGN3 expression 
in D13 progenitors made more monohormonal cells than cells expressing NGN3 earlier, we 
analyzed expression of the individual hormones insulin and glucagon in the endocrine cells 
produced (Figure 10B). The clear segregation of insulin and glucagon expression in those 
endocrine cells suggests the later progenitors, upon NGN3 expression, are capable of becoming 
monohormonal cells in vitro (Figure 10B). However, further characterization of these cells is 
necessary to ensure other pancreatic hormones are not co-expressed. Many of the NGN3 OE cells 
that were insulin+ also expressed the beta-cell marker NKX6.1 (Figure 10C), a characteristic lacking 
in the polyhormonal cells generated during normal differentiation. In contrast, the single insulin+ cell 
identified in control cells did not co-express NKX6.1 (Figure 10C). Previous work from our lab has 
highlighted the extreme importance of NKX6.1 expression for both the differentiation to, and 
maintenance of, functional beta-cells in vivo (Sander, Sussel et al. 2000, Taylor, Liu et al. 2013). 
Up to this point, we had not observed robust NKX6.1 expression in any hormone+ cells generated 
in vitro. While these results are encouraging, more work is required to fully assess the whether 
these hormone+ cells generated via NGN3 overexpression in hESC-derived pancreatic progenitors 
can function as beta cells and secrete insulin in response to glucose stimulation. 
 
DISCUSSION 
The results presented here suggest that NGN3 is both necessary and sufficient to drive 
pancreatic endocrine formation in human cells, as it is in mice. In recent years, conclusive evidence 
in support of these conclusions has been published (McGrath, Watson et al. 2015). To continue to 
dissect the role of NGN3 in pancreatic endocrine specification and build upon this research, 
experiments in which NGN3 expression is rescued at different times during differentiation of NGN3-
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null hESCs could determine whether timing and duration of NGN3 expression dictates the 
pancreatic endocrine subtypes that are formed. Aside from filling a knowledge gap in how NGN3 
controls pancreatic endocrine formation, these experiments could ultimately pave the way for 
researchers to begin to generate whole human islets, complete with all endocrine subtypes, entirely 
in vitro. Although the topic of a cell replacement therapy for diabetes often solely focuses on the 
beta cell, there is evidence that other endocrine subtypes such as the glucagon-producing alpha 
cells may be vital for maintaining proper beta cell function (Rodriguez-Diaz, Dando et al. 2011). 
Therefore, generating whole pancreatic islets from hESCs may, someday become the gold 
standard of cell replacement therapies for diabetes. 
A comprehensive understanding of the importance of proper spatial and temporal 
expression of transcription factors, like NGN3, during differentiation is crucial to advancing the state 
of the art of in vitro generation of hESC-based cell and organ replacement therapies (Trounson and 
DeWitt 2016). As the knowledge of the scientific community grows, one can envision a future in 
which generation of various different cell types from hESCs can be achieved entirely through 
precise manipulation of external signals, without the need for viral transductions or transfections of 
exogenous DNA or RNA. These methods could eventually be applied to patient-derived induced 
pluripotent cells to generate patient-specific replacement cells that are safe and effective and do 
not require immunosuppression, providing a virtually limitless source of “self-donor” material for 
patients who suffer from any number of ailments. 
 
METHODS 
Human embryonic stem cell (hESC) culture and expansion. 
CyT49 human embryonic stem cells (NIH registration number: 0041) were maintained as 
previously described (Xie, Everett et al. 2013, Wang, Yue et al. 2015). Briefly, expansion of hESCs 
was achieved by passing cells every 3 days and culturing in sterile T-75 culture flasks (Corning®). 
Accutase™ (Innovative Cell Technologies) was used for cell dissociation and flasks were coated 
with a 10% (vol/vol) solution of human AB serum (Valley Biomedical). Flasks were seeded with 4 x 
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106 hESCs for 3 days of culture before passaging. Fresh maintenance media was supplied for 
hESCs each day and consisted of DMEM/F12 (Life Technologies) supplemented with 10% (vol/vol) 
KnockOut™ Serum Replacement XenoFree (Life Technologies), 0.1 mM MEM non-essential 
amino acids (Mediatech), 1X GlutaMAX™ (Life Technologies), 1% (vol/vol) penicillin/streptomycin 
(Life Technologies), 0.1 mM 2-mercaptoethanol (Life Technologies), 10 ng/mL Activin A (R&D 
Systems), and 10 ng/mL Heregulin-β1 (PeproTech). 
 
Pancreatic differentiation of hESCs. 
Pancreatic differentiation was performed as previously described (Schulz, Young et al. 
2012, Xie, Everett et al. 2013, Wang, Yue et al. 2015). Briefly, we used a suspension-based culture 
format to differentiate cells in aggregate form. Undifferentiated aggregates of hESCs were formed 
by re-suspending dissociated cells in hESC maintenance media at a concentration of 1 x 106 
cells/mL and plating 5.5 mL per well of the cell suspension in 6-well ultra-low attachment plates 
(Costar). The cells were cultured overnight on an orbital rotator (Innova2000, New Brunswick 
Scientific) at 95 rpm. After 24 hours the undifferentiated aggregates were washed once with RPMI 
media and supplied with 5.5 mL of Day 0 differentiation media. Thereafter, cells were supplied with 
the fresh media for the appropriate day of differentiation (see below). Cells were continually rotated 
at 95 rpm, or 105 rpm on days 4 through 8 and no media change was performed on Day10. Both 
RPMI (Mediatech) and DMEM High Glucose (HyClone) media were supplemented with 1X 
GlutaMAX™ and 1% penicillin/streptomycin. Human activin A, mouse Wnt3a, human KGF, human 
Noggin, and human EGF were purchased from R&D systems. Other added components included 
FBS (HyClone), B-27® supplement (Life Technologies), Insulin-Transferrin-Selenium (ITS; Life 
Technologies), TGFβ R1 kinase inhibitor IV (EMD Bioscience), KAAD-Cyclopamine (KC; Toronto 
Research Chemicals), and the retinoic receptor agonist TTNPB (RA; Sigma Aldrich). Day-specific 
media differentiation media formulations were as follows: Days 0 and 1: RPMI + 0.2% (v/v) FBS, 
100 ng/mL Activin, 50 ng/mL mouse Wnt3a, 1:5000 ITS. Days 1 and 2: RPMI + 0.2% (v/v) FBS, 
100ng/mL Activin, 1:5000 ITS. Days 2 and 3: RPMI + 0.2% (v/v) FBS, 2.5 mM TGFβ R1 kinase 
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inhibitor IV, 25 ng/mL KGF, 1:1000 ITS. Days 3 – 5: RPMI + 0.2% (v/v) FBS, 25 ng/mL KGF, 1:1000 
ITS. Days 5 – 8: DMEM + 0.5X B-27® Supplement, 3 nM TTNPB, 0.25 mM Cyclopamine, 50 ng/mL 
Noggin. Days 8 – 12: DMEM/B27, 50 ng/mL KGF, 50 ng/mL EGF. 
 
Design and construction of overexpression and knockdown lentiviruses. 
Overexpression lentivirus was constructed using the pRRLSIN.cPPT.PGK-GFP.WPRE 
payload vector backbone. The GFP cassette was replaced by human NGN3 cDNA through 
standard restriction digest and ligation cloning. NGN3 cDNA was generated from hESC genomic 
DNA using the following primers: NGN3-F 5’- ATGACGCCTCAACCCTCG-3’ and NGN3-R 5’-
TCACAGAAAATCTGAGAAAGCC-3’. Knockdown lentivirus was constructed using payload 
vectors containing shRNA sequences targeting NGN3 that have been previously described 
(McGrath, Watson et al. 2015). Lentiviruses were assembled via co-transfection of HEK293T cells 
with either overexpression or knockdown vectors, along with pCMV R8.74 and pMD.G helper 
plasmids. Viral supernatant was collected and concentrated by ultracentrifugation at 19,400 rpm 
for 2 hours using an Optima L-80 XP Ultracentrifuge (Beckman Coulter). To generate NGN3 
knockdown cell lines, undifferentiated hESCs were transduced with lentiviruses containing shRNAs 
targeting NGN3 and maintained as described above, with the addition of 2 µg/mL puromycin to 
select for cells expressing the shRNA. Cells were maintained under antibiotic selection throughout 
expansion prior to seeding for differentiation. In order to overexpress NGN3 during differentiation 
aggregated cells were first dissociated into single cells using Accutase™ and supplied with fresh 
differentiation media for the appropriate day, with 50 µL of viral concentrate added to the media. 
Plates were then placed back on the orbital rotator at 95 rpm at 37 °C overnight, to induce re-
aggregation. Either GFP overexpression or scrambled shRNA viruses served as controls. 
 
Magnetic sorting of pancreatic progenitors 
Magnetic-activated cell sorting (MACS) to isolate pancreatic progenitors from 
polyhormonal cells was performed using the MACS® Cell Separation kit (Miltenyi Biotec). At Day 
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10 of differentiation, hESC-derived cell aggregates were dissociated using the reagents included 
with the MACS® Cell Suspension kit. This and all subsequent steps were carried out according to 
the manufacturer instructions. Primary antibodies targeting the cell-surface proteins used to 
distinguish progenitors from endocrine cells were CD200-APC and CD142-PE (1:10, BD 
Biosciences). Separated cells were collected in wells of new 6-well Ultra-low attachment plates and 
supplied with fresh Day 10 media. For NGN3 overexpression experiments, sorted CD142+ cells 
were transduced with NGN3 overexpression virus prior to placing plates were back on the orbital 
rotator at 95 rpm at 37 °C overnight, to induce re-aggregation, and differentiation was continued 
normally. 
 
Immunofluorescence analysis. 
Cell aggregates derived from hESCs were allowed to settle in microcentrifuge tubes and 
washed twice with PBS before fixation with 4% paraformaldehyde for 30 min at room temperature. 
Fixed cells were washed twice with PBS and incubated overnight at 4 °C in 30% (w/v) sucrose in 
PBS. Cell aggregates were then loaded into disposable embedding molds (VWR), covered in 
Tissue-Tek® O.C.T. Sakura® Finetek compound (VWR) and flash frozen on dry ice to prepare 
frozen blocks. The blocks were sectioned at 10 µm and sections were placed on Superfrost Plus® 
(Thermo Fisher) microscope slides and washed with PBS for 10 min. Slide-mounted cell sections 
were permeabilized and blocked with blocking buffer, consisting of 0.15% (v/v) Triton X-100 
(Sigma) and 1% (v/v) normal donkey serum (Jackson Immuno Research Laboratories) in PBS, for 
1 hour at room temperature. Slides were then incubated overnight at 4 °C with primary antibody 
solutions. The following day slides were washed five times with PBS and incubated for 1 hour at 
room temperature with secondary antibody solutions. Cells were washed five times with PBS before 
coverslips were applied. All antibodies were diluted in blocking buffer at the ratios indicated below. 
Primary antibodies used were: sheep anti-NGN3 (1:300, R&D Systems); rabbit anti-SOX9 (1:1000 
dilution, Millipore); goat anti-PDX1 (1:500 dilution, Abcam); mouse anti-NKX6.1 (1:300 dilution, 
Developmental Studies Hybridoma Bank); rabbit anti-CHGA (1:1000, DAKO); guinea pig anti-INS 
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(1:500, DAKO), mouse anti-GCG (1:500, Sigma), rabbit anti-SST (1:500, DAKO). Secondary 
antibodies against sheep, rabbit, goat, mouse and guinea pig were Alexa488-, Cy3- and Cy5-
conjugated donkey antibodies and were used at dilutions of 1:1000, 1:2000, and 1:250, respectively 
(Jackson Immuno Research Laboratories). Representative images were obtained with a Zeiss 
Axio-Observer-Z1 microscope equipped with a Zeiss ApoTome and AxioCam digital camera. 
Figures were prepared in Adobe Creative Suite 5. 
 
Reverse Transcription and Quantitative PCR (RT-qPCR) analysis. 
Total RNA was isolated from hESC-derived cell aggregates using the RNeasy® Micro Kit 
(Qiagen). Synthesis of cDNA was performed using the iScript™ cDNA Synthesis Kit (Bio-Rad) and 
500 ng of isolated RNA per reaction. PCR reactions were performed in triplicate with 10 ng of 
template cDNA per reaction using a CFX96™ Real-Time PCR Detection System and the iQ™ 
SYBR® Green Supermix (Bio-Rad). PCR of the TATA binding protein (TBP) coding sequence was 
used as an internal control and relative expression was quantified via double delta CT analysis. 
Primers used for RT-qPCR are as follows: 
INS-F: 5’-AAGAGGCCATCAAGCAGATCA  
INS-R: 5’-CAGGAGGCGCATCCACA  
GCG-F: 5’-AAGCATTTACTTTGTGGCTGGATT  
GCG-R: 5’-TGATCTGGATTTCTCCTCTGTGTCT  
SST-F: 5’-CCCCAGACTCCGTCAGTTTC 
SST-R: 5’-TCCGTCTGGTTGGGTTCAG 
NGN3-F: 5’-ACTGTCCAAGTGACCCGTGA 
NGN3-R: 5’-TCAGTGCCAACTCGCTCTTAG 
TBP-F: 5’-ATTAAGGGAGGGAGTGGCAC 
TBP-R: 5’-GCTTTGCTTCCCTTTCCCAA 
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FIGURES 
 
 
 
Figure 7. Pancreatic Differentiation of hESCs. (A) Schematic of directed differentiation protocol 
from human embryonic stem cells (hESCs), through lineage intermediates, to hormone+ cells. 
Timing of expression for key stage-specific protein markers shown below stage names. Exogenous 
differentiation factors added to media are listed for the appropriate stages. (B) Relative mRNA 
levels during differentiation show peak activation of NGN3 before that of the trunk progenitor 
markers NKX6.1, PDX1 and SOX9. Relative expression values shown as percentages (0 – 100) of 
each gene’s maximum expression across the differentiation time course. 
  
KC 
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Figure 8. Knockdown of NGN3 Prevents Formation of hESC-derived Pancreatic Endocrine Cells. 
(A) Immunofluorescence analysis for NGN3 expression (top) and RT-qPCR analysis of mRNA 
levels for NGN3 and its downstream target, NEUROD1 at D8 of differentiation. (B) End-stage 
analysis for insulin and glucagon show diminished expression of both hormones in NGN3 KD cells. 
(C) NGN3 KD cells still express the pancreatic trunk progenitor markers NKX6.1 and PDX1. Scale 
bars, 50 µM. 
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Figure 9. Overexpression of NGN3 at Different Times During Pancreatic Differentiation of hESCs. 
(A) Immunofluorescence analysis for NGN3 and chromogranin A (CHGA) 1, 3 and 5 days after D7 
transduction of NGN3 OE. (B) Immunofluorescence (above) and RT-qPCR (below) analysis for 
insulin and glucagon 3 and 6 days after D7 transduction. End-stage RT-qPCR analysis for NGN3 
also shown (below). (C) Immunofluorescence (left) and RT-qPCR (right) analysis for NGN3, insulin 
and glucagon 3 days after D10 transduction. End-stage RT-qPCR analysis for NGN3 also shown 
(right). Scale bars, 50 µM. 
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Figure 10. Overexpression of NGN3 in Magnetically Sorted CD142+ Pancreatic Progenitors. (A) 
Immunofluorescence analysis for CHGA, NGN3, insulin and glucagon 5 and 9 days after 
transduction of NGN3 OE in CD142+ D13 progenitors isolated by MACS. (B) Immunofluorescence 
analysis for insulin and NKX6.1 9 days after transduction of NGN3 OE in CD142+ D13 progenitors. 
Individual insulin+ cells highlighted (white boxes) and magnified. Scale bars, 50 µM. 
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CONCLUSION 
From neurons and heart muscle to liver and pancreas and everything in between, each of 
these specialized cell types stems from pluripotent cells containing genomes identical to one 
another. How then can these highly distinct cell types arise from cells that all contain the exact 
same genes? This is one of the most important, unanswered questions of developmental biology . 
Research into this question has identified that modulation of the three-dimensional structure of DNA 
within the nucleus as a major component influencing gene expression (Shogren-Knaak, Ishii et al. 
2006, Martino, Kueng et al. 2009). The reshaping of chromatin in a cell type-specific manner instills 
different developmental competencies in different cells, allowing them to navigate through various 
lineage intermediates of their respective cell fates even while exposed to the same inductive cues 
(Xie, Everett et al. 2013, Wang, Yue et al. 2015). 
While in vivo animal studies have provided incredible insights into development and 
disease, and still serve as important models, hPSC-based in vitro differentiation systems provide 
the unique ability to dissect such developmental mechanisms, on a molecular level often not 
feasible in animal models. Indeed, the shear amount of cellular material required for certain assays 
like mapping the chromatin landscape throughout embryonic development would require a 
staggering number animal sacrifices and the associated costs quickly make these kinds of studies 
in animals impractical. Fortunately, in vitro models like the hESC-based in vitro pancreatic 
differentiation system employed here, have provided us and others with the tools required for 
systematic and meticulous examination of the various mechanisms involved in cell differentiation 
and development.  
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